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1. Introduction on calix[n]arenes 
Calix[n]arenes
1
 are macrocycles belonging to the 
[1.1.1.1.]metacyclophane family, in which p-substituted 
phenolic units are linked together via methylene bridges. The 
calixarene family consists of 17 cyclooligomers, ranging from 













                                                 
1
 (a) Vicens, J.; Harrowfield, J. Calixarenes in the Nanoworld, Springer: Dordrecht, 
2007; (b) Gutsche, C. D. Calixarenes Revisited, Royal Society of Chemistry: 
Cambridge, 1998; (c) Bohmer, V. The Chemistry of Phenols, Wiley: Chichester, 
2003; (d) Gutsche, C. D. Calixarenes, An Introduction, Royal Society of Chemistry: 
Cambridge, 2008.  
2 
 
Regarding the calix[n]arene nomenclature, the word 
“calixarene” was coined by C. David Gutsche, because the p-
t-butylcalix[4]arene resembled the shape of a  Greek vase 
called calyx krater  (Figure 1.2), while "n" between square 
brackets indicates the number of phenolic components of the 








           calyx krater                  p-t-butylcalix[4]arene 
 
Figure 1.2  
 
The calixarenes can exist in several conformations because 
the phenolic units freely rotate around the methylene bridge. 
Regarding the p-tert-butylcalix[4]arene, it adopts  both in 
solution and in the solid state the cone conformation, with the 
four phenolic hydroxyl groups engaged in a cyclic network of 
hydrogen bonds. In this case it is possible to distinguish two 
regions, the Exo or Upper Rim and the Endo or Lower Rim 
(Figure 1.2). 
Exo or Upper Rim 






Both the lower and upper rim can be easily functionalized, 
allowing the introduction of several functional groups such as 
ethers and esters by alkylation of the hydroxyl groups, and the 






1.1 Applications in host-guest chemistry 
Together with cyclodextrins, cucurbiturils and crown ethers, 
calixarenes constitute the major classes of supramolecular 
hosts. They are bowl-shaped macrocycle and their cavity is 
able to host small molecules or ions. The synthetic versatility 
of the calixarenes enables them to act as a framework that can 
support a broad range of binding, signaling or other 
functionalities. Thus, currently many examples  have been 
reported of calixarene-based hosts for the recognition of 
cations, anions and neutral molecules with the aim to develop 
new materials with potential applications as sensors
3
 or 
membranes for the removal of pollutants.
4
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Regarding the cationic recognition, an interesting example is 
the p-sulfonatocalix[7]arene, a water soluble compound, that 
shows good affinity toward some organic quaternary 
ammonium salts of environmental relevance, such as Diquat 
and Paraquat.
5
  Interestingly, in the solid state the dicationic 
Diquat guest is encapsulated in a molecular capsule 

























                                                 
5
 Caeta, C.; Caruso, T.; Mincolelli, M.; Troisi, F.; Vasca, E.; Neri, P. Tetrahedron, 
2008, 64, 5370-5378. 
6
 Erra, L.; Tedesco, C.; Vaughan, G.; Brunelli, M.; Troisi, F.; Gaeta, C.; Neri, P. 
































R R R R
O OR = H or NO2
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The coordination chemistry of anions has gained more interest 
in the last twenty years. The design of anion receptors is 
really challenging. Anions are larger then isoelectronic 
cations, thus electrostatic binding interactions are less 
effective. Moreover anion species have different geometries, 
thus a high degree of design is required for the synthesis of 
suitable complementary receptors for anionic guests. 
Functional groups like amides, ureas, thioureas and pyrroles 
are very attractive for this purpose and they have recently 




An example is the study of the binding properties toward 
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The derivatives shown in Figure 1.4 are able to bind anions 
such as dihydrogen phosphate, fluoride, acetate and benzoate. 
Particularly, these derivatives are able to discriminate 
efficiently the H2PO4
-
 anion, with a selectivity more than 38-
fold higher than those for the acetate and benzoate anions. 
This selectivity can be explained by the planar trigonal 
arrangement of NHs groups of three amidopyrrole units, that 




Calixarenes have the characteristic to organize themselves in 
the solid state through  weak interactions. They form 
supramolecular frameworks with lattice voids that can be 
occupied by guest molecules.
9
 Thus, p-H-calix[4]arene 
(Figure 1.5a) is able to form crystal structures in which three 
calixarene units adopt a cyclic arrangement, with an 
approximately spherical shape, held together only by van der 
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Figure 1.5 a) p-H-calix[4]arene; b) trimeric arrangement of p-
H-calix[4]arene; c) space filling representation of p-H-
calix[4]arene@CF3Br. 
 
These trimers form a hexagonal close-packed (hcp) lattice 




freons and also methane (Figure 1.5c). The gases are retained 
even at relatively high temperatures and low pressures. Thus, 
this solid-state self-assembly of calix[4]arenes reported in 
2002 by Atwood and coworkers,
9
 results in a supramolecular 
system with potential application in gas storage. 
 
 
1.2 Biological applications of calix[n]arenes 
Over the last 30 years a growing interest has been direct 
toward the biomolecular recognition of calixarene derivatives 
and more in particular to the interaction with druggable 
target(s).
11,12
 At this regard one of the first report by Cornforth 
and coworkers in 1955 showed that the p-octyl-calix[8]arene 




More recently, p-sulfonatocalix[n]arenes have interesting 
antiviral activity and they find potential use in the treatment 
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Brit. J. Pharmacol. 1955, 10, 73-86; (b) D’Arcy Hart, P.; Armstrong, J. A.; Brodaty, 
E. Infetc. Immun. 1996, 64, 1491-1493. 
9 
 
of viruses such as AIDS and Herpes.
14,15
 
Some of the most fascinating results in the biological activity 
of calixarenes have been achieved by Hamilton and his co-
workers, that described a series of peptidocalix[4]arene 
derivatives active as antiangiogenic and anticancer agents.
16
 
In this report Hamilton and coworkers studied a series of 
protein surface binders constituted by a calix[4]arene 










Figure 1.6 growth factor binders functionalized with: a) 
peptide loops; b) isophthalate groups. 
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These compounds were able to bind the surface of the 
platelet-derived growth factor (PDGF), which is a potent 
inducer of growth and mobility in a large number of cell types 
such as endothelium, fibroblasts and smooth muscle.
17
 This 
growth factor plays a central role in cell proliferation, 
angiogenesis and apoptosis inhibition.
18
 PDGF or PDGF 
receptors are implicated in the development of many 
malignant diseases such as cancer, and their overexpression is 




The growth factor binders (GFBs in Figure 1.6) reported by 
Hamilton are able to disrupt the interactions between PDGF 
and its cell surface receptor, a tyrosine kinase. Particularly, 
GFB-111 (Figure 1.6) binds the regions of PDGF that are 
involved in binding to its receptor (IC50 = 250 nM). The 
treatment of nude mice bearing human tumors with GFB-111 
resulted in significant inhibition of tumor growth and 
angiogenesis. Human glioblastoma (U87MG)-implanted in 
nude mice treated with GFB-111 at 50, 100 and 200 mg/kg 
per day were subject to a tumor growth inhibition of 56, 81 
and 88% respectively after a few weeks (Figure 1.7). 
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 Hannink, M.; Donoghue, D. J. Biochim. Biophys. Acta, 1989, 989, 1-10. 
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 (a) Jones, S. M.; Kazlauskas, A. FEBS Lett. 2001, 490, 110-116; (b) Heldin, C. H.; 
Ostman, A.; Ronnstrand, L. Biochim. Biophys. Acta 1998, 1378, F79-F113. 
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Figure 1.7 Inhibition of tumor growth in nude mice by GFB-
111. 
 
However GFB-111 has some limitations due to the difficulty 
of their synthesis and their low solubility that causes 
aggregation in water. These drawbacks were overcome with 
the synthesis of a second generation of GFBs in which the 
peptide loops at the upper rim of the calix[4]arene were 
replaced by acyclic isophthalate groups (Figure 1.6). With 
these modifications the molecular weight was significantly 
reduced without compromising the biological activity (IC50 = 
190 nM).  
The derivatives previously reported prevents the binding of 
PDGF to its receptor and consequently the biological activity 
of the growth factor (PDGF) is disrupted, resulting in a 
significant inhibition of the tumor growth. Hence, these 
12 
 
results suggest that the disruption of protein-protein 
interactions can be considered a promising approach for 
anticancer therapy.  
 
There have been several studies on the biomolecular 
recognition abilities of calixarenes towards drugguble 








A series of N-linked tetrapeptidocalix[4]arenes (Figure 1.8) 
were found to be able to inhibit the activity of 
transglutaminases.
23
 These enzymes catalyze an acyl transfer 
reaction between the -carboxamide group of the protein-
bound glutamine residue and the primary amino group of the 
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Figure 1.8 Tetrapeptidocalix[4]arenes 
 
When overexpressed, transglutaminases may be involved in a 




The tetrapeptidocalix[4]arenes showed in vitro inhibition 
activity against tissue and microbial transglutaminase by 
means of protein surface recognition on a region 
noncomprising the enzyme active site.  
Hystone deacetylases are enzymes involved in the epigenetic 
regulation of gene expression as they are responsible for the 
removal of acetyl groups from lysine residues in hystones. 
Their dysfunctions or overexpressions are involved in 
                                                 
25
 Kim, S. Y.; Jeitner, T. M.; Steinert, P. M. Neurochem. Int. 2002, 40, 85-103. 
14 
 
carcinogenesis and tumor progression.
26
 Thus HDAC 
inhibition could be a promising approach in anticancer 
therapy.  
Alkyl and arylamidocalix[4]arenes were synthesized and 













Figure 1.9 Calixarene-based hystone deacetylase inhibitors. 
 
They are in a cone conformation, with three hydrophobic 
residues at the exo rim as well as a carbon aliphatic chain with 
a terminal carboxylic acid. Moreover the hydrophobic groups 
at the exo rim (especially the aromatic ones) can establish 
hydrophobic interactions with the pockets on the enzyme 
surface (Figure 1.10). 
                                                 
26
 Baylin, S. B.; Ohm, J. E. Nat. Rev. Cancer 2006, 6, 107-116. 
27
 Chini, M. G.; Terracciano, S.; Riccio, R.; Bifulco, G.; Ciao, R.; Gaeta, C.; Troisi, F.; 














Figure 1.10 3D model of the binding mode of 
amidocalixarenes and the enzyme binding site. 
 
The inhibition of HDAC activity was evaluated in vitro. 
Particularly the derivative bearing 2-naphtyl residues showed 
a high inhibitory activity (IC50 = 0.14 μM), a value that is 
comparable (only seven-fold higher) to the activity of  









All the studies reported above show the potential and actual 
applications of calix[n]arenes in the biomolecular recognition. 
The synthetic and conformational versatility, together with the 
ability of establishing multiple interactions with biomolecules, 
make calixarenes a class of compounds suitable for potential 
























2. DNA intercalators in anticancer therapy 
DNA-Intercalators
28 
are molecules able to interact reversibly 
with the DNA double helix. Many of them are currently used 
as drug for the treatment of ovarian and breast cancers.
29 
Regarding the structure of the DNA-intercalating agents they 
show common structural features such as the presence of 
planar polyaromatic systems
30
 (Figure 2.1) which intercalate 




Currently it is well known that the antitumor activity of the 
intercalator-based drugs is due to their ability to stabilize the 
DNA-intercalator-topoisomerase II ternary complex,
32
 
causing thus the inhibition of cellular DNA-dependent 
replication and transcription processes. 
Nucleic acids interact reversibly with a broad range of 
chemical species that include, metal ions and their complexes, 
                                                 
28
 Martinez, R.; Chacon-Garcia, L. Curr. Med. Chem. 2005, 12, 127-151. 
29
 Zhang, N.; Yang, Q. Med. Hypotheses 2009, 73, 1058-1059. 
30
 Lown, J. W. Anthracyclines and Anthracenedienone-Based Anticancer Agents, 
Elsevier Science: Amsterdam 1988. 
31
 Neidle, S. Principles of Nucleic Acid Structure, Academic Press, Elsevier Inc.: 
London, 2008. 
32
 Ioanoviciu A., Antony S., Pommier Y., Staker B. L., Stewart L., Cushman M. J. 




small organic molecules and proteins. There are generally 
three mechanism for DNA interaction: a) binding along the 
exterior of the helix through non specific and primarily 
electrostatic interactions;
33
 b) specific groove-binding 
interactions of the bound molecule with the edges of the base-
pairs in the major or minor grooves of nucleic acids;
34
 c) 
intercalation of planar or approximately planar aromatic ring 
systems between the base-pairs.
35
  
This last mode of binding is very common for a large number 
of polycyclic aromatic hydrocarbons (PAHs). Intercalation 
requires changes in the sugar-phosphate torsional angles in 
order to accommodate the aromatic compound.
36
 The creation 
of an intercalation site causes the separation of the base-pairs 
with a lengthening of the double helix and a decrease in the 
helical twist at the intercalation site (unwinding).  
Initially all the spaces between the base-pairs are potential 
binding sites. However intercalators can bind at alternate 
base-pairs sites, thus when an intercalator binds at one 
particular site, the binding of another molecule at the adjacent 
site is inhibited. 
                                                 
33
 Such, D.; Chaires, J. B. Bioorg. Med. Chem. 1995, 3, 723-728. 
34
 Wilson, W. D. Nucleic Acids in Chemistry and Biology, IRL Press: Oxford, 1990 
35
 Braña, M. F.; Cacho, M.; Gradillas, A.; de Pascual-Teresa, B.; Ramos, A. Current 
Pharmaceutical Design, 2001, 7, 1745-1780. 
36
 Waring, M. J.  Ann. Rev. Biochem. 1981, 50, 159-192. 
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In the last years many intercalation compounds have been 
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 (a) Henry, D. W Cancer Treat. Rep.1979, 63, 845-854; (b) Hsiang, Y. H.; Liu, L. F.; 
Wall, M. C.; Nicholas, A. W.; Manikumar, G.; Kirshenbaum, S.; Silber, R.; Potmesil, 
M. Cancer Res., 1989, 49, 4385-4389. 
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Many classical intercalators such as those described above are 
inhibitors of topoisomerase II.  
Topoisomerases are enzymes responsible for the unwinding 
and overwinding of DNA during the replication and 
transcription processes.
38
 Topoisomerase II is highly 
expressed in rapidly proliferating cells and is therefore an 
attractive target for antitumor drugs. 
The antitumor activity of intercalator agents is closely related 
to the ability of interacting with the DNA-topoisomerase II 
complex. Upon intercalation with DNA they form a stable 
ternary complex drug-DNA-topoisomerase, preventing the 
reconnection of the DNA strands.
39
 As a consequence the cell 
replication process is inhibited, causing cell death. 
Several studies have focused on bisintercalating compounds,
40
 
which generally consist of two aromatic units connected 
together by a linker which can vary in length and rigidity in 
order to modify the binding affinity or specificity.
35
 
Bisintercalators show higher DNA binding affinities and 
slower dissociation rates, as well as a greater potential for 
sequence selectivity. Several bisintercalators have been 
                                                 
38
 Champoux, J. J. Annu. Rev. Biochem. 2001, 70, 369-413. 
39
 (a) Ross, W. E.; Bradley, M. O. Biochim. Biophys. Acta, 1981, 654, 129-134; (b) 
Tewey, K. M.; Rowe, T. C.; Yang, L.; Halligan, B. D.; Liu, L. F. Science 1984, 226, 
466-468. 
40
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Drug Des. 1993, 8, 257-268; (b) Braña, M. F.; Castellano, J. M.; Moran, M.; Perez 
de Vega, M. J.; Perron, D.; Conlon, D.; Bousquet, P. F.; Romerdhal, C. A.; Robinson, 
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developed as potential anticancer drugs, such as 



















Figure 2.2 Examples of bisintercalators. 
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Recently Rescifina and his co-workers reported the synthesis 
of isoxazolidinyl polycyclic aromatic hydrocarbons 
(isoxazolidinyl-PAH) as potential DNA intercalators.
42
 These 
derivatives have been obtained by 1,3-dipolar cycloaddition 
between an appropriate nitrone and allyl alcohol. 
The cycloaddition reactions were performed by microwave 









The ability of isoxazolidinyl-PAHs to interact with DNA was 
then investigated. Binding studies have shown that all the 
derivatives bind to some extent to DNA by intercalation and 
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 (a) Rescifina, A.; Zagni, C.; Romeo, G.; Sortino, S. Bioorg. Med. Chem. 2012, 20, 
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                        IC50 (μM)   
Cell Line   R1=Me 
R2=9-phenant 
cis 











125 128 112 127 
THP-1  
(leukemia) 
169 148 107 192 
U937  
(lymphoma) 
153 154 111 193 
 
 




2.1 Calixarene based DNA intercalators – 
Results and discussion 
 
The first topic of this PhD thesis has been inspired by the 
results reported by Rescifina and co-workers. In particular, we 
have designed and synthesized the calixarene based DNA-
intercalators in Figure 2.4 bearing isoxazolidinyl-polycyclic 
aromatic hydrocarbon units at the exo rim.  
 
Several calixarene conjugates presenting polycyclic aromatic 
hydrocarbons (PAH) can be designed. A schematic 
representation is shown in Figure 2.4, in which a 
IC50 is the concentration of the drug required to cause 50% reduction in 




calix[4]arene scaffold presents isoxazolidinyl-PAH units at 
the exo rim. The nature of the bond between the calixarene 
and the isoxazolidinyl unit can be of different types, such as 












Figure 2.4 Designed isoxazolidinyl-PAH-calixarene 
conjugates. 
 
Among the different possibilities, a first class of derivatives 
was synthesized by esterification of a cone-shaped 
calix[4]arene-diacyl chloride 1 with trans- or cis-
pyrenylisoxazolidinyl alcohols 2a-b (Figure 2.5).
43
 These 
compounds could act as potential DNA intercalators. Their 
                                                 
43
 Rescifina, A.; Zagni, C.; Mineo, P. G.; Giofrè, S. V.; Chiacchio, U.; Tommasone, S.; 
Talotta, C.; Gaeta, C.; Neri, P. Eur. J. Org. Chem. 2014, 7605-7613. 
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2.1.1 Synthesis of the calixarene conjugates 
 
The diacyl chloride calixarene 1 was obtained by conversion 
of the calix[4]arene-dicarboxylic acid
44
 with thionyl chloride. 
The synthesis of 1 is illustrated in Scheme 2.1. 
                                                 
44
 Sansone, F.; Barboso, S.; Casnati, A.; Fabbi, M.; Pochini, A.; Ugozzoli, F, Ungaro, 





Scheme 2.1 Synthesis of diacyl chloride calix[4]arene 1.
45  
 
Starting from p-t-Bu-calix[4]arene 3, the tert-butyl groups at 
the exo rim were removed via retro Friedel-Crafts reaction, in 
                                                 
45
 Casnati, A.; Di Modugno, E.; Fabbi, M.; Pelizzi, N.; Pochini, A.; Sansone, F.; 
Tarzia, G.; Ungaro, R. Bioorg. Med. Chem. Lett. 1996, 6, 2699–2704. 
27 
 
presence of AlCl3 and phenol.
46
 Then the lower rim was 
selectively alkylated with K2CO3 and n-PrI in acetonitrile at 
reflux.
47
 This was possible thanks to the different acidity of 
the hydroxyl groups. Indeed, after the first alkylation, the 
removal of the second phenolic proton takes place at the distal 
position, because the resulting anion is stabilized by two 














Figure 2.6 Selective dialkylation of 4. 
                                                 
46
 Böhmer, V.; Rathay, D.; Kämmerer, H. Org. Prep. Proced. Int. 1978, 10, 113. 
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28 
 
Following a procedure reported by Ungaro and coworkers,
48
 
two formyl groups were then introduced at the calixarene 
upper rim by Gross formylation reaction,2
d
 affording product 
6. In this case the formylation occurs on the aromatic rings 
bearing the free hydroxyl groups. To perform an exhaustive 
alkylation of the lower rim a protection of the formyl groups 
with trimethyl orthoformate was necessary. After removal of 
the protective groups via acid treatment, the aldehyde groups 
of 8 were oxidized to carboxylic acids with NaClO and 
NH2SO3H in CHCl3/Acetone.
44 Finally the treatment of 8 with 
thionyl chloride in dry CH2Cl2 led to the desired product 1.
45 
PAH-calixarenes derivatives 10-12 in Figure 2.7 were finally 
obtained by coupling of the diacyl chloride 1 with the 
corresponding racemic alcohols (±)-2a or (±)-2b using 
pyridine or triethylamine as base.43 After a standard work-up 
the calixarene/pyrenylisoxazolidinyl conjugates were isolated 
by silica gel column chromatography. In particular, starting 
by the alcohol (±)-2a, a monosubstituted derivative (±)-10a 
the derivative with C2 symmetry (±)-11a, and a meso 
compound 12a were obtained in 15%, 10% and 8% yields 
respectively. Starting by the alcohol (±)-2b, then  a 
monosubstituted derivative (±)-10b and the derivative with C2 
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symmetry (±)-11b, were isolated in 10% and 11% yields 


























Concerning the stereochemistry of the bis-derivatives 11-12, 
the symmetry was assigned on the basis of the number of 
NMR resonances. For instance the 
1
H NMR spectrum of 11a 
showed two triplets at δ = 3.69 (J = 6.3 Hz, 4H) and 4.04 ppm 
(J = 7.6 Hz, 4H) and two triplets at δ = 0.91 and 1.07 ppm 
regarding the OCH2 and terminal CH3 of the propyl chains 
















H NMR spectrum of 11a (400 MHz, CDCl3, 
298K). 
 
Besides, the 2D HSQC spectrum showed two cross-peaks at δ 
= 3.69/76.9 and 4.04/76.7 ppm relative to a direct C-H 
31 
 
correlation between the OCH2 protons and their respective 
carbons (Figure 2.9). At last, to support the C2 symmetry, the 
13
C NMR spectrum showed only one signal related to the 
carbonyl group of the ester bond and two signals for the 

















Figure 2.9 Expansion of 2D HSQC spectrum of 11a (400 
















Figure 2.10 Expansion of 
13
C NMR spectrum of 11a (100 
MHz, CDCl3, 298K). 
 
Similarly, the stereochemistry of 12a was evident from the 
1
H 
NMR spectrum in C6D6, in which were found three OCH2 
signals at δ = 3.86, 3.70 and 3.69 ppm (4H, 2H and 2H 
respectively). These observations were characteristic of the 
presence of a σh symmetry plane bisecting the unsubstituted 


























As expected, the 
1
H NMR spectra of the monosubstituted 
derivatives (±)10a and (±)10b were complex due to the lack 
of any symmetry element. For instance, the 
1
H NMR 
spectrum of 10b showed four AX systems for the methylene 
bridges in the region between 3.10-3.18 ppm and 4.40-4.53 
ppm. A similar set of signals was found for 10a.  
The characterization of all these compounds was confirmed 




2.1.2 Biological studies49 
 
At this point the ability of compounds 10-12  to inhibit in 
vitro the proliferation of cancer cells was evaluated.
49
 These 
studies were performed by Rescifina’s group. Compounds 10-
12 were tested against three different human tumor cell lines: 
FTC133 (follicular thyroid carcinoma), 8305C 
(undifferentiated thyroid carcinomas) and U87MG 
(glioblastoma). The cell cultures were incubated with 10-12 
for 24h and the cell growth rates were evaluated by MTT 
reduction assays. The calixarenes were prepared as dimethyl 
sulfoxide stock solutions at 10 and 100 μM concentrations. 
The results of the inhibitory activities of 10-12 are shown in 
Table 2.2 and are compared to the activities of the 
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Compound FTC133 8305C U87MG 
2a 5.88 - 5.55 
2b 5.22 - 5.36 
10a >100 >100 >100 
10b 0.095 0.130 57 
11a >100 >100 >100 
11b 55 55 >100 
12a >100 >100 >100 
 
Table 2.2 The results are expressed as IC50 [μM] (the 
concentration of compound at which 50% of cells are viable) 
and determined by MTT assay. 
 
The most cytotoxic compound was the monosubstituted 
calixarene with cis stereochemistry 10b, which exhibited an 
IC50 value of 95 nM toward FTC133 cells (for this cell line 
Doxorubicin shows IC50 = 9650 nm)
50
. The bis-substituted 
compound 11b showed an IC50 value of 55 μM, which was ca. 
580-fold less cytotoxic than 10b. The other monosubstituted 
calixarene 10a showed a low cytotoxicity, with IC50 values 
higher than 100 μM, thus stereochemistry plays a fundamental 
role in the activity of these compounds, as the cis derivative 
10b was more active than its trans isomer 10a.  
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A lack of activity was found for the bis-substituted 
compounds 11a and 12a. These unexpected results could be 
explained considering the low solubility of the derivatives in 
the culture medium. The IC50 values probably result from 
lower ligand concentrations with respect to those actually 
used. In contrast, the deprotonation of the carboxylic group of 
10b under physiological conditions could increase its 
solubility. However the hydrolysis of the carboxylic acid 
cannot be the only explanation for the high cytotoxcity of 
10b. The calixarene derivative is 58-fold more potent than the 
precursor 2b, thus the calixarene core must clearly have a 
prominent implication in the biological activity. 
 
 
2.1.3 Circular Dichroism49 
 
The pyrenylisoxazolidinylcalix[4]arene conjugates above 
described were designed as potential DNA intercalators. To 
prove the intercalation between base pairs some studies of 
circular dichroism (CD) were performed. Particularly the 
attention was focused on the behavior of 10b and 11b which, 
as previously described, turned out to be the most cytotoxic 
compounds. The studies were performed on a poly(dA)-
poly(dT) duplex, which is a duplex of poly(deoxyadenylic-
deoxythymidinic) acid, a repetitive synthetic double-stranded 
37 
 
DNA sequence and a synthetic analog of B-DNA.
43
 
The CD spectrum of poly(dA)-poly(dT) displayed a negative 
peak at λ = 248 and a positive one at λ = 260 nm, due to the 
right-handed helicity and to base stacking respectively.
51
 
In Figure 2.12 the CD tritation spectra of poly(dA)-poly(dT) 














Figure 2.12 CD tritation spectra at 25 °C:  
[poly(dA)–poly(dT)] = 19.7 μm in base pair; [10b] = 0–32 μm 
 
Increasing concentration of 10b led to decreases in the 
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intensities of the signals at λ = 248 and 260 nm, together with 
the appearance of a positive induced CD signal at 342 nm. 
These observations were typical of an intercalative binding 
mode. The changes in the intensities of the CD spectra were 
due to helix unwinding as a result of the distortion of DNA 
upon intercalation. The small positive induced CD signal at λ 
= 342 nm confirmed the intercalation phenomenon, with the 
pyrene moiety perpendicular to the DNA axis. 
Similar CD spectra were observed with the 11b-poly(dA)-
poly(dT) system, but with reduced changes in intensity. 
 
 
2.1.4 Molecular Modeling49 
 
To gain a deeper comprehension of the interaction of the 
calixarene derivatives 10-12 and DNA, a study of molecular 
modeling was performed by Prof. Rescifina and co-workers.
49
 
The compounds with a (3R) configuration for the 
isoxazolidine ring possess the best intercalating properties
42
, 
thus, although the calixarene conjugates are racemates, all 
molecular docking calculations were performed for the (3R) 
stereisomers. Poly(dA–dT)2, poly(dG–dC)2, and poly(dA)–
poly(dT) were simulated as double-stranded dodecamer 
fragments, (dA–dT)2, (dG–dC)2 and poly(dA)–poly(dT), 
respectively. They were constructed in the B-DNA 
39 
 
conformation with the nucleic acids macro implemented in 
the YASARA software
52
 and minimized with the Amber03 
force field.
53
 The simulations of the intercalation were 
performed by the docking methodology.
54
 Each intercalator 
was manually inserted into the middle base-step of each 
fragment from the minor or major groove. Particularly for 
monointercalations the compounds were inserted between the 
sixth and seventh base pairs, while for bisintercalation 
between the fifth and sixth as well as the seventh and eighth 
base pairs, simultaneously. The atom positions of each 
compound were fixed, however the remaining molecules were 
minimized to suitably accommodate the ligand. To obtain the 
best and most reliable docking results, a coarse docking 
simulation was first performed for each complex by applying 
the Lamarckian Genetic Algorithm (LGA) implemented in 
AutoDock 4.2.5.1,
55
 which has been recently demonstrated to 
accurately reproduce the complex crystallographic structures 
of a collection of DNA-binding small ligands.
56
 The best 
ligand position was further subjected to an MD simulation of 
5 ns in a physiological environment (pH = 7.2, H2O, NaCl 
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0.9%) to allow the ligand to be better accommodated in the 
pocket and model the interactions with the groove. At last, 
each ligand was well docked by the LGA with the system 
obtained by MD. Under physiological conditions the 
carboxylic acid moiety in compounds 10 is completely 
dissociated, thus, only the carboxylate form was considered. 
The possibility that the complexation between 10-11 with 
DNA may occur by binding along the grooves was also taken 
into account. The calculated binding energies after 5 ns of 


















Compound (dA-dT)2 dodecamer 
from major groove 
(dA-dT)2 dodecamer 
from minor groove 
2a (intercalated) -9.11 -9.03 
2b (intercalated) -9.68 -9.39 
10a (intercalated) -6.53 -8.83 
10b (intercalated) -6.69 -10.19 
11a (intercalated) -9.22 after 1 ns, -7.36 -9.81 
11b (intercalated) -11.16 after 1 ns, -8.13 -15.51 
10a (groove-bound) -4.66 -7.79 
10b (groove-bound) -4.35 -8.16 
11b (groove-bound) -8.35 -8.79 
 (dG-dC)2 dodecamer 
from major groove 
(dG-dC)2 dodecamer 
from minor groove 
2a (intercalated) -9.28 -9.09 
2b (intercalated) -9.35 -9.23 
10a (intercalated) -6.76 -7.33 
10b (intercalated) -8.91 -10.88 
11a (intercalated) -8.48 -9.05 
11b (intercalated) -10.55 -13.09 
10a (groove-bound) -5.13 -7.54 
10b (groove-bound) -4.41 -8.65 
11b (groove-bound) -8.15 -8.98 
 poly(dA)-poly(dT) 
from major groove 
poly(dA)-poly(dT) 
from major groove 
10b (intercalated) -6.43 -9.92 
10b (groove-bound) -5.72 -6.57 
 
Table 2.3 Calculated binding energies [Kcal/mol] after 5 ns 
of MD simulation. 
 
Intercalation from the major groove and both minor and major 
groove binding can be ruled out on the basis of their lower 
binding energies. The compounds can act as mono or 
bisintercalators that interact preferentially with AT base pairs, 
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penetrating into the DNA double helix from the minor groove. 
The lower cytotoxic activity of the trans stereoisomer 10a 
compared to the cis one 10b could be ascribable to the steric 
hindrance of the N-Me group of the isoxazolidine ring. This 
hypothesis is supported by the lower binding energies of 10a 
compared to 10b (see Table 2.3).  
A graphical representation of 10a and 10b intercalated from 
the minor groove in the (dA-dT)2 dodecamer is shown in 
Figure 2.13. The N-methyl group in the trans compound 10a 
(Figure 2.13, left) is oriented towards the base pairs of the 
DNA fragment. Conversely in the cis isomer 10b the methyl 












Figure 2.13 10a (left) and 10b (right) intercalated from the 
minor groove in the (dA-dT)2 dodecamer. 
43 
 
According to the binding energies in Table 2.3, compounds 
11a and 11b could behave as bisintercalators. In particular, 
the calculate binding energy of -15.51 Kcal/mol for 11b 
presupposes a strong interaction with the DNA, which should 
lead to a biological activity in the submicromolar range. 
Probably the low activity measured (IC50 = 55 μM for 
FTC133) could be ascribable to the low solubility of the 
compound.  
An interesting behavior was observed for both 11a and 11b 
when intercalated from the major groove of poly(dA-dT)2. In 
fact, the examination of the MD simulation trajectories 
revealed that they can act only as monointercalators. After 1 
ns both compounds 11 are bisintercalated into the dodecamer. 
Subsequently one pyrene moiety deintercalates and becomes 
perpendicular to the calixarene exo rim. After 5 ns simulation 
11 is uniquely monointercalated. A representation of the 























Figure 2.14 Representation of 11b intercalated into the (dA-
dT)2 dodecamer from the major groove. After 1 ns of MD 
simulation the compound is bisintercalated (left); after 5 ns 




Nevertheless, the binding energies for these two MD periods 
are smaller than those observed for the intercalation of the 
compounds from the minor groove. Conversely, for the 
interaction with the (dG-dC)2 dodecamer, the bisintercalate 
complexes are stable up to 5 ns of MD simulation (Table 2.3).  
45 
 
Finally, in Figure 2.15 is shown the arrangement of 10b into 














Figure 2.15 Plot representing 10b intercalated into the 
poly(dA)–poly(dT) dodecamer from the minor groove. 
 
 
The pyrenyl unit of 10b is parallel to the long axis of the base 
pairs. This arrangement is in good agreement with the induced 
CD signal at λ = 342 nm observed (Figure 2.12), thus 







In this work we have obtained new PAH-presenting 
calix[4]arene conjugates bearing pyrenylisoxazolidine 
moieties at the exo rim.
43
 The in vitro cytotoxic activity 
against three different human tumor cell lines was tested and 
the most active compound 10b showed an IC50 of 95 nM 
toward FTC133 cell lines (follicular thyroid carcinoma).
43
 
Compared to the pyrenylisoxazolidinyl alcohols 2a-b a 58-
fold increase in activity was observed. Both CD and docking 
studies indicated that these calixarene derivatives are able to 
intercalate DNA from its minor groove.
43 
Unfortunately the bis-substituted compounds did not show the 
expected results, probably because of their low solubility in 
the cell culture medium. With no doubt the results herein 
reported and the information obtained during these studies can 
be used to design and synthesize new DNA-intercalating 











3. Chemical proteomics and drug discovery 
 
Drug discovery is a research process that consists of the 
identification and development of a molecule that produces a 
desired effect in a living organism. Understanding the 
mechanism of action is a main requirement to find a new 
drug. However this request can only be satisfied provided that 
the biomolecular targets of the new potential drug are 
known.
57
  In the last decades the identification of calixarenes 
able to bind a known biomolecular target, has been carried out 
by using two principal strategies: the screening of a library of 
potential candidates
11(c,d),16b




Recently mass spectrometry-based chemical proteomics has 
gained relevance as a novel strategy for the identification of 
possible biological targets.
59
 The interest in this emerging 
approach has grown rapidly thanks to the remarkable 
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technological advances in mass spectrometry.
60
 One of the 
principal chemical-proteomics approaches uses immobilized 
compounds and combines drug affinity chromatography with 




A typical chemical proteomics experiment starts with the 
immobilization of a potential bioactive compound on a solid 
support. There are several commercially available activated 
resins, usually based on sepharose or agarose, that allow the 
attachment of chemical groups such as amino, hydroxyl or 
carboxyl groups. 
A cell extract is then prepared either from cells or tissue and 
this lysate is incubated with the affinity matrix and washed 
extensively before the elution. For nonspecific elution, 
detergents, salts or denaturing agents are used. The specific 
elution can be achieved via the specific cleavage of an 
engineered linker. Subsequently, processing by SDS-PAGE 
and protein digestion with a protease (generally trypsin) 
generates a complex peptide mix, which is analyzed by 
nanoHPLC coupled to nanoESI/MS.  
Finally the results are searched against a protein database to 
identify the proteins bound to the bioactive compound. 
The whole chemical proteomics experiment is described in 
Figure 3.1. 
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A great advantage of this technique is that it can be used to 
probe the whole proteome. Proteins are encountered in their 
natural state, which includes endogenous abundance levels 
and post translational modifications. Besides it is possible to 
use any cell type or tissue, from microorganism to humans. 
Unfortunately chemical proteomics does not provide 
information about functional implications, as there is no 
correlation with the IC50. Thus, although it can give indication 
about specific physical interactions between a compound and 

















3.1 Application of chemical proteomics 
 
The use of this technique has led to the discovery of a variety 
of compound targets, particularly the kinase inhibitors based 
on natural products. The identification of kinase targets has 
been investigated in various diseases such as cancer and 
autoimmune disorders.
61
 Protein kinases are among the most 
investigated drug target classes, so that several kinase 
inhibitors have entered clinical trials in the recent years. 
Chemical proteomics is widely applied to identify possible 
targets of kinase inhibitors through affinity purification from 
cellular extracts. In fact, the advantage of performing the 
experiment using disease-relevant cells enables to study more 




Interestingly chemical proteomics is widely applied for the 
identification of the biomolecular targets of natural products. 
Due to the low abundance, the testing for the biological 
activity of most of the newly discovered natural products is 
limited. Most of these tests are focused on the antibacterial 
and anticancer activity, thus the potential of most natural 
products as drugs and their ability to interfere with biological 
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pathways is unexplored. Therefore the use of natural products 
in chemical proteomics experiments is highly worthwhile.
63
 
For instance, this approach was used to investigate the 
molecular mechanism of action of the antimitotic compound 
diazonamide A, a marine natural product. Chemical 
proteomics led to the discovery that its target, ornithine δ-
amino transferase, plays a fundamental role in mitotic spindle 
assembly and cell division.
64
 
Casapullo and co-workers paid much attention to the 
identification of the macromolecular targets of small bioactive 
compounds.
65
 They disclosed the proteasome inhibitory 
activity of Petrosaspongiolide M (PM), an anti-inflammatory 
marine sesterpene.
65a
 The bioactive compound was covalently 
linked to an activated agarose matrix, which was modified 
with a spacer to avoid steric interference between the ligand-
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Figure 3.3 Preparation of PM-modified beads. 
 
The PM-modified matrix was then incubated with human-
macrophage-derived THP-1 cell extracts. Chemical 
proteomics revealed the ability of Petrosaspongiolide M to 
interact with several components of the proteasome enzymatic 
machinery. Thus the activity of PM on the 20S proteasome 
was tested in vitro by detecting its ability to modulate the 
proteasome-mediated proteolysis of three fluorogenic peptide 
substrates. PM was found to inhibit the proteasomal activity, 
particularly in the chymotrypsin-like site, with an 
effectiveness comparable to MG132, a well-known 
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 have already entered clinical 
trials for the treatment of cancer and stroke patients 
respectively. The proteasome activity of PM, disclosed thanks 
to chemical proteomics, suggests that this molecule could be 
considered as a new lead compound. 
 
Although its limitations, there is no doubt that chemical 
proteomics is a very powerful approach for the investigation 
of new drug targets and the elucidation of the mechanism of 
action of potential drugs. This is particularly relevant when 
the drug candidate is a low abundant compound, such as a 
natural product. Instead of performing a screening of several 
targets for the evaluation of the biological activity of a given 
compound, through a chemical proteomics experiment the 
potential partners can be identified simultaneously.  
Chemical proteomics, in combination with other techniques 
and the recent and continuing technological improvements, 
will find more applications in the coming future and will be a 
even more powerful tool in drug discovery. 
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3.2 Biomolecular recognition abilities of 
calixarenes through the chemoproteomic 
approach - Results and discussion 
 
During this PhD research project, chemical proteomics was 
used to study the biomolecular recognition abilities of 
calix[4]arene derivative bearing acetamido groups at the exo 
rim. This study was performed in collaboration with Prof. 
Casapullo (DIFARMA, University of Salerno) and his 
research group. 
 
Calix[4]arenes bearing amido, urea or thiourea functionalities 
have the potential to establish intermolecular interactions with 
biological compounds, due to their hydrogen-bond donor 
acceptor groups. To evaluate the biomolecular recognition 
abilities through a chemical proteomics approach, the 
calixarene must be functionalized to introduce a suitable 
linker for the subsequent immobilization on the solid support. 
The first derivative to be investigated through this approach 
was the p-acetamidocalix[4]arene 13 (Figure 3.4).
68
 This 
compound combines the hydrogen-bond donor/acceptor 
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abilities of the acetamido groups at the exo rim and the 
hydrophobicity of the calixarene backbone, which should 











Figure 3.4 p-acetamidocalix[4]arene 13. 
 
 
The p-acetamidocalix[4]arene 13 also presents a spacer arm at 
the endo rim, 2-(2-aminoethyldisulfanyl)ethylamine, for the 
immobilization on the solid support. The spacer is necessary 
to minimize the steric hindrance between the calixarene on the 







3.2.1 Synthesis of compound 13 
 
The synthesis of the p-acetamidocalix[4]arene 13 (pAC 13) is 
outlined in Scheme 3.1a-b.  
The derivative 14 bearing three propyl chains at the endo rim 
was obtained by alkylation of p-t-Bu-calix[4]arene 3 with 1-
iodopropane, BaO and Ba(OH)2.
69
 The free phenol ring was 
alkylated with α-bromo-ethylacetate, using NaH as  base in 
dry DMF.
70
 The ester group of 15 was then hydrolyzed with 
NaOH in a mixture of THF/H2O at reflux, affording to 
derivative 16.
71
 Derivative 16 was exhaustively nitrated to the 
exo rim by treatment with HNO3 in presence of CH3COOH  in 
dry CH2Cl2 as solvent. Compound 17
71
 was purified by flash 
column chromatography. The four nitro groups of 17 were 
then reduced to amino groups via catalytic hydrogenation 
with Nickel Raney in DMF.
71
 Subsequently the tetracetamido 
calix[4]arene 19 was obtained by treatment of the tetramino 
compound 18
71
 with acetyl chloride in dry THF.  
The structure of 19 was assigned by spectral analysis. In 
particular, the presence of a molecular ion peak at m/z 859.5 
(M+Na
+
) in the ESI(+) mass spectrum confirmed the 
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molecular formula. The 
1
H NMR spectrum of 19 DMSO-d6 
showed the –NH signals of the amido moieties between δ = 
9.30-9.59 ppm as well as the three singlets for the aromatic 
protons at δ = 6.68 (2H), 6.75 (2H) and 7.04 (4H) ppm. 
(Figure 3.5) The protons of the methylene bridges showed 
signals at δ = 3.06 (d, ArCH2Ar, J = 12.8 Hz, 4H), and 4.29-
4.34 (overlapped, 4H) ppm, while the 
13
C NMR spectrum 
(100 MHz, MeOD, 298K) showed a signal at δ = 154.82 ppm 





















































































H NMR spectrum of 19 (400 MHz, DMSO-d6, 
298 K) 
 
Before the coupling reaction between 19 and the spacer arm, a 
mono-Boc protection of the diamino derivative  20 was 
necessary. This was performed following a quick and simple 
procedure in which the desired product 21 was isolated after 
two extractions.
72
 At first the crude was washed with diethyl 
ether and 1M NaH2PO4 solution (pH = 4.2). Then the aqueous 
layer was basified to pH = 9.0 with 1M NaOH solution and 
washed with ethyl acetate. Finally the organic layer was 
concentrated affording the mono-Boc protected spacer arm 
21. Afterwards the derivative 19 was coupled with the spacer 
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arm 21 with N,N’-dicyclohexylcarbodiimide (DCC) and 
hydroxybenzotriazole (HOBt) in dry DMF, affording 
compound 22. The treatment of 22 with trifluoroacetic acid 
(TFA) in dichloromethane, followed by a short column 
chromatography purification led to the isolation of the desired 





spectroscopy and ESI(+) MS. The presence of a molecular ion 
peak at m/z 971.4 (M+H
+
) in the ESI(+) mass spectrum 
confirmed the molecular formula. The 
1
H-NMR of the final 
product 13 showed the signals of the spacer arm at δ = 2.86 (t, 
CH2NH2, J = 6.4 Hz, 2H), 3.02 (t, CH2S, J = 6.6 Hz, 4H) 
ppm, and the singlet for OCH2C(O) at δ = 4.78 ppm. The 
protons of the methylene bridges showed overlapped signals 
















The treatment with trifluoroacetic acid is a well established 
procedure for the removal of Boc protective groups, almost 
quantitative. Surprisingly in this case compound 13 was 
obtained with only a 50% yield. Probably this low yield is 
ascribable to the degradation of the disulfide bond of the 
spacer arm.  
 
 
3.2.2 Chemical proteomics experiment73 
 
The chemical proteomics experiment (or “fishing” 
experiment) was performed by Prof. Casapullo and co-
workers. Compound 13 was covalently linked to the agarose-
gel activated with 1,1
’
-carbonyldiimidazole (CDI). Thus 13 
was dissolved in acetonitrile containing 30% NaHCO3 and 
1.5% Et3N and incubated with the CDI-agarose beads for 16h. 
The final concentration of 13 was 3μmol per milliliter of resin 
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Figure 3.7 Immobilization of 13 on agarose beads. 
 
Then samples of crude HeLa cells were incubated with the 
pAC 13-modified beads. A calix-free matrix was used as a 
control experiment to discriminate between specific and 
aspecific interactions. The beads were washed three times 
with Phosphate-Buffered Saline (PBS) solution to remove 
aspecific bound proteins. The beads were then treated with 
dithiothretiol (DTT) to break the disulfide bridge of 13 and to 
release in solution the pAC-proteins complexes. The protein 
mixture was purified by SDS-PAGE, digested with trypsin 
and analyzed by mass spectrometry through nanoflow 
reversed-phase HPLC MS/MS. The ten most intense doubly 
and triply charged peptide ions were fragmented and the MS 
spectra were subjected to a Mascot database search. The 
results were compared with those of the free-matrix control 
experiment. Usually this kind of “fishing” experiment gives a 
huge number of potential partners, which is reduced by 
applying a filter of the Mascot scores and the Pep(sig) values. 
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The Mascot score is the probability that an observed match is 
not a random event, while the Pep is the Posterior Error 
Probability, defined as the probability of a random match 
being classed as significant. In this case only proteins with 
Mascot score > 30 and Pep(sig) > 1 were considered, in order 
to obtain results with high trustworthiness. In addition 
keratins were also excluded, as their presence is due to 
accidental operator contamination. To establish which 
proteins were the best potential partners for pAC 13, the 
chemical proteomics experiment was performed three times, 
giving three sets of proteins (Table 3.1). 
 
 
Table 3.1 Proteins identified in each of the three different 
fishing experiments and not detected in the corresponding 
control experiments (Mascot score > 30, Pep(sig) value >1). 
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The intersection of these sets gave only a single protein as 










Figure 3.8 Venn diagram showing the intersection of the 
three sets of all the protein partners identified in the three 
different fishing experiments. 
 
The protein identified was the Protein Disulfide Isomerase 
(PDI), a 57 kDa chaperone protein located in the endoplasmic 
reticulum.
74
 PDI acts as a thiol oxidoreductase, it is able to 
catalyze the formation, breakage and rearrangement of 
disulfide bonds, and thus it is responsible for the regulation of 
oxidative protein folding as well as cell viability.
75
 Several 
studies report that increased PDI levels were found in a 
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 PDI is considered a promising druggable target, 
as the inhibition of its activity leads to apoptosis in cancer. 
The protein has five domains and in particular there are two 
cysteine residues in the a and a’ domains which are essential 














Figure 3.9 Representation of the PDI structure. 
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The linker of derivative 13 has a disulfide bridge, hence it is 
possible to imagine that it may be responsible for the 
interaction with the protein. In order to verify whether the 
disulfide bridge of 13 may have a role in the interaction with 
PDI protein, a sulphur-free analog of 13 was synthesized. The 
new derivative 24 bears four propyl chains at the lower rim 
and four acetamido groups at the upper rim. It was obtained 











Figure 3.10 Synthesis of the tetracetamido calixarene 24. 
 
 
The interaction of 24 with PDI protein was studied through 
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Surface Plasmon Resonance is as a powerful optical detection 
technique for the investigation of biomolecular interactions in 
real time.
80
 A light source passes through a prism, reflects on 
the back side of the sensor chip surface and arrives to the 
detector. At a certain incident angle, known as the resonance 
angle, light is absorbed by the electrons in the metal film on 
the sensor chip, causing them to resonate. These resonating 
electrons are also known as surface plasmons, which are 
sensitive to the surrounding environment. The result is an 
intensity loss in the reflected beam, which appears as a dark 
band on the detector and can be seen as a dip in the SPR 
reflection intensity curve (Figure 3.11). The shape and 
position of the SPR dip can then be used to convey 
information about the sensor surface. SPR is frequently used 
to study molecular binding interaction between free analyte 
molecules in solution and probe molecules which are 
immobilized on the sensor surface. As a molecular binding 
event takes place, the angular position of the dark band shifts 
(Figure 3.11). 
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Figure 3.11 General principles of the SPR technique. 
 
 
When an analyte with affinity to the immobilized ligand is 
introduced into the system, then binding events can be 
observed. Initially there are many binding sites available, 
resulting in a rapid increase in SPR response as the analyte 
binds to the ligand. While sample is continually injected into 
the system, analyte molecules continue to bind and the 
number of available binding sites decreases, corresponding to 
a decrease in the binding rate, until the system approaches 
71 
 
equilibrium and the number of molecules binding and 
unbinding becomes equal. When no more analyte is 
introduced into the system the molecules will continue to 
unbind, resulting in a decrease in SPR response (Figure 3.12). 
The association constant ka can be extracted for the behavior 
of the binding response. Likewise the dissociation constant kd 
can be extracted from the unbinding response. The ratio of 
these two rate constants affords the binding affinity (KD) of 









For our purposes PDI was immobilized on the surface of a 
CM5 chip, then solutions of 24 at three different 
concentrations (0.1-10 μM) were injected. The interaction 
experiments were carried out at a flow rate of 10 μl/min and 
the dissociation time was set at 600 seconds. Compound 24 
was also injected over two different proteins, Peroxiredoxin 1 
and Lamin B1, and over the unfunctionalized SPR chip, as a 
negative control. 
The results showed a considerable affinity between the PDI 
and pAC 24, with KD = 11 μM, (Figure 3.13) while no 
binding was observed in the control experiments (Figure 
3.14-16). These results confirmed the interactions between 
PDI and 24 and also allowed to rule out any participation of 
the disulfide bridge of 13.  
 
 
Figure 3.13 Sensograms obtained after injections of pAC 24 




Figure 3.14 Sensorgrams obtained after injections of pAC 24  
on the immobilized Peroxiredoxin 1. 
 
 
Figure 3.15 Sensorgrams obtained after injections of pAC 24  
on the immobilized Lamin B1. 
 
 
Figure 3.16 Sensorgrams obtained after injections of pAC 24 
on the unfunctionalized SPR chip. 
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3.2.3 Molecular Docking 
 
In order to gain more insight into the interaction of pAC 24 
with PDI, a molecular docking study was performed. Protein 
Disulfide Isomerase presents four thioredoxin domains, a, a’, 
b and b’, arranged in the shape of a twisted “U” (Figure 3.9). 
The two active sites are located in the a and a’ domains, while 
the b’ domain contains a large hydrophobic pocket able to 
accommodate the substrates. The inside surface of the “U” is 
enriched in hydrophobic residues, facilitating interactions 
with misfolded proteins. Calixarene 24 is able to occupy the 
inside surface of the “U”. The binding with the protein occurs 


























Figure 3.17 3D model of the binding mode of pAC 24 
(depicted as a blue CKP representation) in the hydrophobic 
pocket in the b’ domain of PDI. 
 
In particular, 24 established two hydrogen bonds with Trp396 
and His438, as well as π-stacking interactions between an 
aromatic ring of the calixarene core and Phe249 (Figure 
3.18a). Moreover, the docking studies showed the 
establishment of van der Waals interactions between the 
hydrophobic walls of 24 and the apolar chains of isoleucine 
(Ile), phenylalanine (Phe) and leucine (Leu) amino acid 





Figure 3.18 Interactions between 24 and PDI: (a) hydrogen 
bonds between amide groups of pAC 24 (in a green ball-and-
77 
 
stick representation) and the TRP396 and HIS432 residues (in 
magenta) and π-stacking interactions with PHE249; (b) 
hydrophobic interactions of pAC 24 (in a green CPK model) 
with PHE, ILE and LEU amino acids. 
 
 
The amino acid Trp396, located in the immediate proximity 
of the active site containing Cys397, plays an essential role in 
the redox-regulated conformational change between the 
reduced and oxidized forms of PDI.
81
 This conformational 
change modulates the chaperone activity of PDI protein. It 
was reported that the mutation of Trp396 significantly impairs 
the redox-regulated conformational changes of PDI. Thus, the 
hydrogen-bond interaction between 24 and Trp396 could 
affect the catalytic activity of the enzyme by interfering with 
conformational change between reduced and oxidized PDI. In 
addition, the binding of the calixarene in the hydrophobic 
pocket of the protein could prevent the binding of other 
substrates. 
Moreover the inhibition constant obtained by docking 
calculations is Ki = 6.23 μM, a value that is comparable to that 
obtained by SPR analysis (KD = 11 μM).  
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The role of the acetamido groups is crucial for the interaction 
with the protein. In fact, the molecular docking was also 
performed on the p-tert-butyl analogue of 24, which has no 
possibility to establish hydrogen bonds. In this case the 
calixarene derivative showed a poor affinity for the PDI 
protein, with a Ki = 8.23 mM. 
 
 
3.2.4 Biological activity studies73,82 
 
Both the SPR analysis and Molecular Docking confirmed the 
ability of the p-tetracetamidocalix[4]arene 24 to bind the PDI 
protein. The next step was the investigation of the possible 
biological relevance of 24. Considering that PDI is involved 
in the regulation of protein folding by promoting the 
rearrangement of disulfide bonds in substrate proteins, the 
potential ability of 24 to modulate the PDI activity was 
evaluated through an in vitro test based on the enzyme-
catalyzed reduction of insulin, performed by Prof. Casapullo 
and co-workers.
73
 In particular the test was based on the 
spectrophotometric measurement of the aggregation of 
reduced insulin chains. PDI reduces the insulin disulfide 
bonds in the presence of dithiothretiol (DTT) and the 
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aggregation of the reduced insulin chains can be measured at 
620 nm.  
PDI protein (0.8 μM) was exposed to different concentrations 
of pAC 24 (50 and 100 μM) at 37 °C for 30 min in a sodium 
phosphate buffer. Then a mixture of EDTA, DTT and insulin 
was added and the reaction was monitored every 5 minutes at 
620 nm. The experiment was repeated in absence of 24 as a 
control and the specific PDI activities were estimated by 
subtracting the absorbance of the control buffer (Figure 3.19). 
 
 
Figure 3.19 Effect of 24 on the PDI catalytic reduction of 
insulin 
 
The plots in Figure 3.19 clearly showed that the PDI activity 
was impaired in the presence of pAC 24 in a concentration-
dependent fashion. Therefore the interaction between the 
calixarene and the PDI had a significant impact on the 
function of the protein. 
80 
 
Furthermore, thanks to a collaboration with Dr. Beatrice 
Macchi the in vitro ability of pAC 24 to inhibit the viability 
and metabolic activity of cancer cells was evaluated.
82
 The 
derivative was tested against two different cell lines: CAL-27 
(oral adenosquamous carcinoma cell line) and PC-3 (human 
prostate cancer cell line). 
The cell lines were incubated for 24 h with dimethylsulfoxide 
solutions of compound 24 at different concentrations. The cell 
viability was evaluated by a trypan blue exclusion test and the 
metabolic activity through a MTS reduction assay. The cells 
were also incubated with a known chemotherapeutic drug, 7-
ethyl-10-hydroxycamptothecin (SN38) and a commercial 
synthetic PDI inhibitor 16F16
83




Figure 3.20 Chemical structures of SN38 and 16F16. 
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The results of the biological tests are expressed in Table 3.2 
as IC50 and CC50 values for the viability and metabolic assay 
respectively. 
 





24 CAL-27 20.5±0.8 31±4 
24 PC-3 24.5±0.9 283±10 














IC50  is the inhibitory concentration required to inhibit 50% of cell 
viability; 
b
CC50 is the metabolic activity cytotoxic inhibitory concentration 50%, 
evaluated in the CAL-27 and PC3 cell lines by MTS assay. 
 
Table 3.2. Evaluation of the cytotoxicity of pAC 24 in 
comparison with SN38 and 16F16. 
 
The information obtained from the biological assays were 
really interesting.
68
 The calixarene derivative 24 was 
cytotoxic toward both the cell lines, with IC50 values of 20.5 
and 24.5 μM for CAL-27 and PC-3 respectively, while the 
IC50 values of SN38 were slightly lower. Interestingly 24 
showed the same ability of the commercial PDI inhibitor 
16F16 to inhibit PC-3 cell proliferation. In fact their IC50 
overlapped, thus suggesting a similar action mode. 
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Other interesting consideration can be made on the basis of 
the evaluation of the metabolic inhibitory effect. Particularly 
the CC50 values of 24 are higher than those for SN38 and 
16F16. In the ideal situation IC50 concentrations lower than 
CC50 values are desirable, with CC50 values as high as 
possible. The ratio SI = CC50/IC50 is a value that gives 
information about the selectivity of a drug (SI = selectivity 
index). The higher the index the more selective the compound 
will be toward a pathogen. 
The CC50 value of 24 for PC-3 cell line is 283 μM, which is 
20 time higher than the commercial inhibitor 16F16. As a 
consequence the selectivity index for 24 is SI = 11.5, a really 
promising result, that indicates that pAC 24 has a good 




3.2.5 Synthesis of an advanced intermediate for a new 
calixarene ligand 
 
The interesting results achieved with derivative pAC 24 
encouraged us to deepen the study of the biomolecular 
recognition abilities of novel calixarene derivatives through 
the chemical proteomics approach.  
The derivative 24, bearing four acetamido groups as hydrogen 
83 
 
bond donor/acceptor sites, was chosen as a basic compound 
for a preliminary investigation. Probably a more interesting 
behavior could be observed for a more complex derivative. 
Thus the next step in this PhD research project was the 
synthesis of a new calixarene derivative bearing different 
substituents at the exo rim and to evaluate its recognition 
properties. The designed compound 25 presents four L-




Figure 3.21 Structure of the p-tetrahistidinecalix[4]arene 25 
 
Differently by pAC 24, the derivative 25 presents multiple 
hydrogen bond donor/acceptor sites and thus could establish 
multiple interactions with proteins. Indeed, as well as the 
amido groups directly bound at the para position on the 
calixarene aromatic rings, the designed compound 25 also 
84 
 
presents four amino groups of the amino acid portion, as well 
as two nitrogen atoms for each imidazole ring. The presence 
of all these possible binding sites could lead to the formation 
of new protein-calixarene complexes. The synthetic strategy 
for compound 25 is depicted in Scheme 3.2a-b.  
In this case the synthetic approach was slightly different from 
the synthesis of pAC 13. In fact compound 25 present Boc-
protected amino groups to avoid competition reaction during 









Scheme 3.2b Synthesis of 25. 
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The tetranitro calix[4]arene 26
70
 was obtained by exhaustive 
nitration of the p-tert-butylated precursor 15.
70
 Then the nitro 
groups were reduced via Nickel Raney hydrogenation, 
affording the tetraminocalix[4]arene 27.
70
 The latter was used 
for the coupling with the desired amino acid, with 
(Benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) and N,N-
diisopropylethilamine (DIPEA) as coupling reagents in dry 
DMF. A commercial N
α
-Boc protected histidine was used for 
this purpose. In this case the carbonyl functionality at the 
calixarene endo rim was an ester group to avoid the formation 
of undesired side products during the coupling reaction. 
Therefore the ester group of 28 was hydrolyzed to carboxylic 
acid with lithium hydroxide in THF at room temperature, 
affording compound 29 in quantitative yields. The 
1
H NMR 
spectrum of 29 showed the presence of the signals of the Boc 
groups at δ = 1.34-1.39 ppm and the singlet of OCH2COOH at 
δ = 4.73 ppm. The aromatic protons showed signals at δ = 
6.77, 6.89 ppm and δ = 7.22-7.30 ppm, overlapped with the 
protons of the imidazole rings. Finally at δ = 8.56-8.63 were 







H NMR spectrum of 29 (400 MHz, MeOD, 
298K). 
A Fmoc-protected spacer arm 30, suitably synthetized, could 
be coupled to the carboxylic functionality of 29, affording 
compound 31. The removal of the Fmoc-protective group by 
treatment with piperidine in DMF cpuld lead to the isolation 
of the final product 25 (Scheme 3.2b). At last, the removal of 
Boc-groups could be performed after the immobilization on 











In this chapter a MS-based chemical proteomics approach was 
used to investigate the biomolecular recognition properties of 
calixarene derivatives bearing acetamido groups at the exo 
rim.
68
 In particular this study revealed that p-acetamido 
calixarenes were able to bind the protein disulfide isomerase 
(PDI). The interaction between the derivative 24 and the PDI 
protein was deeply investigated through SPR analysis and 
molecular docking calculations.
68
 Compund 24 was able to 
bind the protein inside the hydrophobic pocket in the b’ 
domain, via the formation of hydrogen bonds through the 
acetamido groups, as well as van der Waals interactions 
through the calixarene scaffold and amino acid residues. 
Biological in vitro tests showed that pAC 24 was able to 
impair the PDI chaperone activity.
68
 Besides it showed 
cytotoxic and cytostatic activity toward CAL-27 and PC-3 
tumor cell lines.
68
 On the basis of these results, a new 
derivative presenting histidine moieties at the exo rim was 






























4. Multivalent systems in glycosidase inhibition 
 
Several systems in biology interact through multiple 
simultaneous molecular contacts. In the last few years this 
concept was adopted as new strategy for the design and 
development of drug candidates.  
Multivalency is the ability of a molecule to bind another 
molecule via multiple simultaneous non-covalent 
interactions.
84
 The valency represents the number of binding 
functionalities for a given compound. Multiple simultaneous 
interactions provide higher specificity and thermodynamic 
and kinetic stability compared to a single interaction. 
Therefore multivalent systems usually show affinity 
enhancement compared to the corresponding monovalent 
ligand. This behavior is known as “the multivalent effect”.
85
  
The multivalent effect is a consequence of several binding 
modes (Figure 4.1). The binding event between a ligand and 
its receptor is a reversible process, thus if the 
association/dissociation processes are fast enough the 
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multivalent effect can be explained  in terms of statistical 
rebinding events. In fact, the high local concentration of 
ligand should favor the rebinding of the substrate (Figure 
4.1a). Other mechanisms such as favorable non-specific 
interactions (Figure 4.1b-c) and the presence of secondary 
binding interactions (subsite binding) can also be possible 
(Figure 4.1d).  
 
 




Recently glycosidase inhibitors have gained considerable 
clinical relevance.
86
 The selective hydrolysis of glycosidic 
bonds in carbohydrates and glycoconjugates is extremely 
diffused in living organisms and is indeed involved in a wide 
range of key cellular processes in biological systems.
87
 This 
process is found in a wide range of diseases such as diabetes, 
viral infection and tumor metastasis.
88
 Very recently there 
have been enormous advancement in the research for 
glycosidase inhibitors thanks to the discovery of iminosugar-
based multivalent clusters.
89
 Applications of this inhibitors to 
glycosidases of therapeutic interest have led to very promising 
results in the field of rare genetic diseases such as cystic 
fibrosis
90
 and Gaucher disease
91
. The major advances in the 
area of multivalent effect in glycosidase inhibition have been 
achieved with iminosugar clusters synthesized by Cu
I
-
catalyzed azide-alkyne cycloaddition (CuAAC),
92
 in which 
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iminosugars with a terminal azido functionality are grafted 




4.1 Applications of multivalency in glycosidase 
inhibition 
Since 1-deoxynojirimycin (DNJ) is a glycosidase inhibitor, it 
was chosen as ligand for the synthesis of several multivalent 





One of the first studies on glycosidase inhibition through high 
valency clusters was based on a C60 platform. Multivalent 
fullerene-based adducts were prepared by CuAAC with 
twelve DNJ units (Figure 4.3).
93
 For the first time strong 
affinity enhancements were observed, up to three orders of 
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magnitude with respect to a single DNJ unit. In particular, the 
best affinity enhancement was observed with the dodecavalent 
DNJ cluster with a C6 linker, toward Jack bean α-
mannosidase. A relative inhibition potency increase of almost 




Figure 4.3 C60-based iminosugar cluster and inhibition 






Even better results were achieved using β-cyclodextrins 
(βCD) as scaffolds.
94
 In fact, as well as allowing the 
construction of high valency systems, the advantage of the β-
cyclodextrin core relies in the different spatial orientation of 
the ligands. With appropriate functionalization 
methodologies, the iminosugar units can be grafted either on 
the primary or secondary face, or even on both of them.  
The multivalent inhibitory effect was evaluated for a series of 
hepta- or 14-valent β-CD-based iminosugar clusters, with 
different ligands and alkyl spacer lengths (C6 and C9).  
The nature of the scaffold is crucial for the modulation of the 
inhibitory activity and selectivity. In fact, while the C60 based 
iminosugar cluster showed multivalent effects for other 
glycosidases, like isomaltase and naringinase, the β-CD-based 
analogous, with similar valency and with same ligand (DNJ) 
and alkyl spacer length (C6), manifested  affinity 
enhancements toward α-mannosidase only.  
The best affinity enhancements were observed for a 14-valent 
DNJ cluster,  which showed inhibitory activity against Jack 
bean α-mannosidase in the nanomolar range (Figure 4.4).   
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The 14-valent DNJ cluster with a C9 linker showed an 
enormous multivalent effect, with an affinity enhancement 
over the corresponding monovalent ligand of almost four 
orders of magnitude. The inhibition potency of each ligand 
was increased more than 600-fold (rp/n = 610). 
Other studies were carried on different scaffolds with 
different spatial orientations, such as porphyrins.
95
 Moreover 
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very recently first examples of cyclopeptoid-based iminosugar 
clusters were reported. The derivatives showed significant 
inhibitory multivalent effect for α-mannosidase.
96




4.2 Calix[n]arenes as scaffolds for multivalent 
systems 
Calix[n]arenes are particularly suitable as scaffolds for the 
synthesis of multivalent ligands, thanks to their variable 
number of  reactive position for attaching the ligand functions 
and well defined different conformations. 
The introduction of sugar moieties (D-glucose, N-acetyl-D-
glucosamine, D-galactose etc.) at the exo rim of a 
calix[8]arene core for the synthesis of potential protein 
surface binders was reported.
97
  
Tetravalent calix[4]arene iminosugar clusters were also 
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Figure 4.5 Tetravalent calix[4]arene clusters with different 
spatial orientation. 
 
Although the identical valency, very different inhibition 
profiles were observed, thus indicating that the spatial 
distribution of the ligands is crucial for the inhibitory activity. 
 
Applications of tetravalent and octavalent calixarene based 
clusters with sialic acid moieties were found in the inhibition 
of viral activities.
98
 The clusters were obtained by copper-
catalyzed cycloaddition of a propargyl thiosialoside with a 
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calix[4]arene platform bearing azido groups (Figure 4.6). 
 
 
Figure 4.6 Representation of an octavalent sialoside 
calix[4]arene cluster. 
 
The derivatives were able to inhibit the hemagglutination and 
the viral infectivity mediated both by BK and influenza A 








4.3 Multivalent iminosugar calix[8]arene 
conjugates – Results and discussion 
On the basis of the considerations reported above, the 
attention was focused on the synthesis of multivalent 
iminosugar-calix[8]arene conjugates 32-33 (Figure 4.7). 
These compounds have been obtained by Cu
I
-catalysed azide-
alkyne cycloaddition (CuAAC) between polyalkyne 
calix[8]arene scaffolds and azide-armed iminosugars. The 
calix[8]arene cores can ensure a high valency, up to eight 
sugar unit per compound (32a-b), which can be modulated by 
the presence of an intramolecular bridge (33a-b).  
 




The intramolecular bridge was designed to evaluate whether a 
more rigid conformation is able to influence the potential 
inhibitory activity. 
This project was developed in collaboration with Prof. 
Philippe Compain from the University of Strasbourg.  
The glycosidase inhibition abilities of glycoconjugates 32-33 




4.3.1 Synthesis of the multivalent iminosugar-
calix[8]arene conjugates 
 
Calix[8]arenes conjugates 32-33 were obtained by Cu
I
-
catalyzed azide-alkyne cycloaddition (CuAAC) between 
calixarene scaffolds 36-37, which present propargyl groups at 
the endo rim, and azide-armed DNJ units with different alkyl 






Scheme 4.1a  
 
Polyalkyne calix[8]arenes 36-37 were synthesized by 
alkylation of the corresponding calix[8]arenes with propargyl 
bromide, using Cs2CO3 as a base and acetone as solvent. The 
bridged calix[8]arene 35 was obtained by a procedure which 
allows the selective alkylation at the 1,5-position.
99
 This was 
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possible thanks to the template effect of Cs
+
. Indeed the 
calix[8]arene adopts a bend conformation in which the 
phenolic groups in positions 1 and 5 face each other and are 






-catalyzed azide-alkyne cycloaddition 
(CuAAC) was performed on both propargylated 
calix[8]arenes 36 and 37. Two different azide-armed DNJ 
iminosugars were used (Scheme 4.1b), with different alkyl 
chains (C6 and C9) to evaluate the influence of the spacer 
length in the inhibitory activity. The cycloaddition reactions 
were performed by dissolving the calix[8]arene derivative in 
DMF in an ACE pressure tube. Then a solution of 
Cu2SO4
.
5H2O and sodium ascorbate in water was added and 
the reaction mixture was heated under microwave irradiation 
105 
 
at 800 W for 20-30 minutes. To remove the copper salts the 
crude products were treated with a solution of 
CH3CN/AcOEt/30w%NH4OH and filtrated on a small pad of 
silica. After flash column chromatography on silica gel 






















































C NMR spectra of derivative 38a are reported as 
example. Due to the C8 symmetry of 38a, the 
1
H NMR 
spectrum in CDCl3 (Figure 4.9) showed one singlet at δ = 
0.89 ppm relative to t-Bu groups, one signal for the aromatic 
hydrogen atoms at δ = 6.80 ppm and the hydrogen for the 










C NMR spectrum (Figure 4.10) showed the 
signal of the tert-butyl groups at 31.46 ppm and four signals 
for the carbonyl groups of the iminosugar units between 169 







C NMR spectrum of 38a (75 MHz, CDCl3, 
298K). 
 
Conversely the NMR spectra of 39a-b were more 
complicated. In fact, due to the presence of the intramolecular 
bridge, the derivatives have a C2 symmetry. The 
1
H NMR 
spectrum of derivative 39a (Figure 4.11) showed two sets of 
signals for the hydrogen on the C1-position of the iminosugar 
units at 3.10 and 3.18 ppm which integrate for four and two 
protons respectively. These two different types of proton 
showed correlation with the corresponding geminal partners at 
δ = 2.26-2.30 (overlapped). The singlet at δ = 3.32 ppm was 
attributed to the aliphatic protons of the intramolecular bridge, 
while the corresponding aromatic protons were found at δ = 
5.82 ppm. The signals of the aromatic protons of the 
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calix[8]arene core were found at δ = 6.58, 6.61, 6.95, 6.98 and 
7.22-7.28 ppm (overlapped), while the hydrogen atoms on the 
triazole rings were found at δ = 7.22-7.28 (overlapped with 





H NMR spectrum of 39a (600 MHz, CDCl3, 
298K). 
 
In addition, the 
13
C NMR spectrum of 39a showed two 
signals related to the atoms in C1-position at δ = 53.06 a 
53.19 ppm, as well as several overlapped signals for the 







C NMR spectrum of 39a (150 MHz, CDCl3, 
298 K). 
 
The last step of the syntheses was the removal of the acetyl 
groups of the iminosugar units. Each calixarene derivative 
was dissolved in dry methanol, then NaOMe was added and 
the reaction mixture was stirred at room temperature. 
Afterwards methanol and water were added until complete 
dissolution. Dowex 50WX8-200 ion-exchange resin was 
added until pH=6-7 was reached. Finally the solution was 
filtered and the solvent was removed under reduced pressure 
affording the desired final multivalent iminosugar 

























4.3.2 Glycosidase inhibition studies100 
 
Once the synthesis of 32a-b and 33a-b was completed, the 
inhibitory activity and the eventual multivalent effect were 
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 In collaboration with Prof. P. Compain, Laboratoire de Synthèse Organique et 
Molécules Bioactives, University of Strasbourg. 
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evaluated. Preliminary inhibition studies were carried on Jack 
bean α-mannosidase by Prof. Compain and co-workers.
100
 
The inhibitory activities were determined by 
spectrophotochemically measuring the residual hydrolytic 
activities of the enzyme against p-nitrophenyl-α-D-
mannopyranoside. A series of assay medium containing α-
mannosidase in the presence or absence of various 
concentration of inhibitor were prepared and the release of p-
nitrophenol was measured at 380 nm. The results were 
interesting and promising.  
 
 
Table 4.1 Jack bean α-mannosidase inhibition studies. 
 
The compounds displayed a multivalent effect comparable to 
cyclodextrin-based systems of similar valencies.
94
 The 
bridged calix[8]arene core gave slightly better multivalent 
effects, especially with the iminosugars bearing longer alkyl 
113 
 
chains. In fact the most potent inhibitor was compound 33b, 
which showed inhibition potency increase of 495-fold 
compared to the corresponding monovalent ligand and a 82-
fold increase of activity per iminosugar unit. The evaluation 




4.3.3 Higher valency iminosugar clusters100 
 
Recently a convergent strategy for the synthesis of high-
valency iminosugar clusters was reported.
101
 The strategy is 
based on two successive Cu
I
-catalyzed azide-alkyne 
cycloadditions. With this approach azide-armed iminosugar 
dendrons can be grafted on the desired polyalkyne scaffold, 
thus tripling the initial valency. We decided to use this 
approach for the synthesis of higher valency iminosugar 
calix[8]arene conjugates, whose synthetic strategy is reported 
in Scheme 4.2a-b. 
The DNJ iminosugar with longer alkyl chain (C9) was chosen 
for this purpose, as it gave the better affinity enhancements 
(See Table 4.1). A first Cu
I
-catalyzed azide-alkyne 
cycloadditions was performed between DNJ-C9 and the 
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trivalent scaffold 40 in order to obtain the trivalent iminosugar 
dendron 41. The latter was then converted in the 
corresponding azide 42 by treatment with 










Afterwards the trivalent azide 42 was grafted on the two 
calix[8]arene scaffolds 36 and 37 with a second Cu
I
-catalyzed 
azide-alkyne cycloadditions, affording compounds 43 and 44. 
The final products 45-46 were obtained after the acetyl groups 
on the iminosugar units were removed by deprotection with 
MeOH/H2O and ion exchange resin (Scheme 4.2b). 
The characterization and the evaluation of the multivalent 
effect in glycosidase inhibition of the clusters described above 




4.4 A new ligation strategy for the synthesis of 
glycoconjugates 
 
During the three years of my PhD studies I had the 
opportunity to spend six months in Montpellier (FR) at the 
Institut des Biomolécules Max Mousseron (IBMM), in the 
Glycochemistry and Molecular Recognition (GMR) team, 
under the supervision of Professor Alberto Marra. During that 
period the attention was focused on the investigation of a new 
ligation strategy for the synthesis of glycoconjugates, with 
potential application in the field of multivalency. 
Sulfonyl halides are very useful substrates in organic 
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synthesis. Quite important compounds are sulfonyl chlorides 
as they are key intermediates for the synthesis of 
sulfonamides, widely employed in medicinal chemistry for 
the development of new therapeutic agents.
102
 Although 
aromatic sulfonyl chlorides are quite stable, many aliphatic 
and heteroaromatic sulfonyl chlorides encounter synthetic 
problems. For instance they are poor sulfonylating agents as 
they undergo dehydrochlorination under mild basic 
condition.
103
 Moreover they are unstable and cannot be 
commercialized.  
A good alternative are sulfonyl fluorides, as they are resistant 
to reduction and more stable in different conditions. Moreover 
recently sulfonyl fluorides have become very attractive 
reagents for click reactions.
104
 Nothing has been so far 
reported about this class of compound bearing sophisticated 
substituents such as carbohydrate residues. 
The aim of this research was to develop a synthetic approach 
for the realization of carbohydrate sulfonyl fluorides and their 
conversion into sulfonamides via aminolysis with aliphatic 
amines. This approach could then be applied to the synthesis 
of multivalent glycoconjugates (Figure 4.14). 
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4.4.1 Results and discussion 
 
At first much attention was dedicated to the preparation of 
anomeric sulfonyl fluorides. Galactosyl thiol 47 was used as a 
substrate,  as it was easily accessible. Several attempts were 
made, attempting both the conversion of the corresponding 
sulfonyl chloride by halogen exchange reaction and the direct 











Several conditions were used for the conversion of 47 in the 
sulfonyl chloride 48 (method a), however the reaction was 
unsuccessful and the thiol was transformed into the 
corresponding disulfide. The direct conversion of 47 in 50 
(method b) led probably to the formation of the sulfonyl 
chloride as intermediate generated in situ. However instead of 
leading to the desired sulfonyl fluoride by halogen exchange, 
the substrate decomposed to give SO2 and the corresponding 
anomeric glycosyl chloride. Also the attempt to generate the 
sulfonyl chloride from the sulfonate 49 and the transformation 
into the anomeric sulfonyl fluoride 50 by one-pot-
chlorination-halogen exchange (method c) was unsuccessful. 
120 
 
After these discouraging results we decided to desist from 
continuing with this approach. 
Afterwards the attention was focused on the introduction of an 
alkyl tether between the anomeric position and the sulfonyl 
group. For this purpose was used the known
105
 C-glycoside 
thioacetate 53, which could be obtained starting from simple 
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The first step was a C-glycosylation reaction at the anomeric 
position of glucose pentacetate 51 with allyltrimethylsilane, 
which afforded compound 52. Then a thiolene reaction 
between 52 and thioacetic acid was performed to obtain the 
thioacetate 53. The latter was treated with Oxone to give the 
corresponding sulfonate salt 54 isolated by column 
chromatography in good yield. The sulfonate 54 was then 
transformed into the sulfonyl fluoride 55 via one-pot two-step 
chlorination reaction with SOCl2 and triphenylphosphine and 
subsequent halogen exchange with potassium fluoride. The 
designed sulfonyl fluoride 55 was isolated by chromatography 
on a short column of silica gel. The product was very stable 
and it did not show any evidence of degradation even after 









H NMR spectrum of 55 (400 MHz, CDCl3, 
298K). 
 
Subsequently the potential application of the sulfonyl fluoride 
in aminolysis reaction was explored. Using benzylamine as 
nucleophile, a series of reactions were performed in order to 
find the optimized conditions. All the parameters like the 







Table 4.2  
 
The results indicated that the reaction performed in DMF at 
80 °C for 3 hours led to the isolation of sulfonamide 56 with 
the highest yield (90%). 
Once the optimal conditions were found, the aminolysis 
reaction was extended to other aliphatic amines, to verify the 
applicability of the approach. The reaction with cyclohexyl 
amine and the more hindered dibutyl amine afforded the 
124 
 
desired sulfonamides, with 97% and 45% yield respectively 
(Figure 4.16). Unfortunately no reaction occurred with 
aromatic amines such as p-cyano and p-methoxy aniline, even 
with longer reaction times. However the sulfonyl fluoride was 





These are only preliminary studies, however the results 
obtained suggest the applicability of the sulfonyl fluorides for 
the synthesis of sulfamides by aminolysis reaction with 
aliphatic amines. This approach was applied to simple 





The concept of multivalency and its application in the field of 
glycosidase inhibition was described in this chapter. This 
approach was applied to calix[8]arenes derivatives, for the 
synthesis of multivalent iminosugar-based clusters. 
Compounds 32a-b and 33a-b were obtained by Cu
I
-catalyzed 
azide-alkyne cycloadditions between azide-armed 
iminosugars and calix[8]arenes bearing propargyl groups. The 
inhibitory activity of these compounds toward α-mannosidase 
was evaluated.
100
 The compounds showed a good multivalent 
effect.  
Higher valency iminosugar clusters 45-46 were also 
synthesized and the evaluation of the multivalent effect in 
glycosidase inhibition is currently under investigation.
100
  
Moreover, the investigation on a new ligation strategy for the 
synthesis of glycoconjugates was reported. The study was 
performed at the Institut des Biomolecules Max Mousseron in 
Montpellier (FR), thanks to a collaboration with Professor 






























5. Experimental section 
All chemicals were reagent grade and were used without 
further purification. Anhydrous solvents were purchased from 
Aldrich. When necessary compounds were dried in vacuo 
over CaCl2. Reaction temperatures were measured externally. 
Reactions were monitored by TLC on Merck silica gel plates 
(0.25 mm) and visualized by UV light, or by sprying with 
H2SO4-Ce(SO4)2 or phosphomolybdic acid. Melting points 
were determined with a Kofler apparatus. Elemental analyses 
were performed with a Perkin–Elmer elemental analyzer. 
ESI(+)-MS measurements were performed on a Waters QTof 
Premiere mass spectrometer equipped with electrospray ion 
source, using a mixture of H2O/CH3CN (1:1) and 5% 
HCOOH as solvent. Flash chromatography was performed on 
Merck silica gel (60, 40-63 μm).  
1D NMR spectra were recorded on a Bruker Avance-600 
spectrometer [600 (
1
H) and 150 MHz (
13
C)], Bruker Avance-
400 spectrometer [400 (
1
H) and 100 MHz (
13
C)], Bruker 
Avance-300 spectrometer [300 (
1
H) and 75 MHz (
13
C)] and 
Bruker Avance-250 spectrometer [250 (
1
H) and 63 MHz 
(
13




5.1  Calixarene based DNA intercalators 
 
General comments: The circular dichroism spectra were 
recorded with a JASCO J-815 spectropolarimeter equipped 
with a 150 W xenon lamp. The ellipticity was obtained by 
calibrating the instruments with a 0.06% (w/v) aqueous 
solution of ammonium d-10-camphorsulfonate and with a 
0.08% (w/v) aqueous solution of 
tris(ethylenediamine)cobalt(III) chloride complex {(–)-Δ-
[Co(en)3]-Cl3}2·NaCl·6H2O. The measurements were 
performed at a constant temperature of 25 °C in quartz cells 
and were corrected for the contribution from the cell and 
solvent. The temperature was controlled by a Jasco PTC-
423S/15 Peltier-type temperature control system cooled with 
an external water circulator. The spectra were corrected to 
take into account the dilution effect after each addition. The 
HPLC system consisted of a Jasco PU-2089 Plus pump and a 
Jasco MD-2010 Plus multiwavelength detector. The HPLC 
column was a Waters Spherisorb® 10 μm CN 10_250 mm 







 were synthesized according to 
literature procedures. Poly(dA)–poly(dT) sodium salt was 
purchased from Sigma–Aldrich. Water was purified through a 
Millipore Milli-Q system. All CD experiments were 
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conducted in 10–2 m phosphate buffer at pH = 7.4 containing 
0.1 m NaCl. The pH of the solution was measured with a 
glass electrode. The concentrations of polynucleotides in base 
pairs were determined by absorption spectroscopy by using 




 at 260 nm. 
 
 
Synthesis of 10a–12a: Compound 1 (0.105 g, 0.147 mmol) 
and (±)-2a (0.233 g, 0.735 mmol) were dissolved in dry 
CH2Cl2 (15 mL), and then dry Et3N (0.101 mL, 0.735 mmol) 
was added. The reaction mixture was stirred at room 
temperature for 48 h. Then, the mixture was washed twice 
with H2O, the organic phase was dried with Na2SO4, and the 
solvent was removed under reduced pressure. The products 
were isolated by silica gel flash column chromatography 
(CH2Cl2/Et2O, 96:4). Compounds (±)-11a and 12a were 
purified by HPLC (mobile phase: hexane/isopropyl alcohol, 




Compound (±)-10a: 22 mg, 15% yield. ESI(+) MS: m/z = 
981.7 [M + H]+, 1003.1 [M + Na]+. M.p. _200 °C (dec.). 
1
H 
NMR (400 MHz, CDCl3, 298 K): δ = 0.97–1.01 (overlapped, 
OCH2CH2CH3, 12H), 1.87–1.96 (overlapped, OCH2CH2CH3, 
8H), 2.66 and 2.83 (br. AB, CH2isox, 2H), 2.78 (br. s, CH3N, 
3H), 3.18–3.26 (overlapped, ArCH2Ar, 4H), 3.80–3.85 
(overlapped, OCH2CH2CH3, 4H), 3.90–3.96 (overlapped, 
OCH2CH2CH3, 4H), 4.41–4.48 (overlapped, Ar-CH2Ar, 4H), 
4.45 and 4.56 (AB, C(O)OCH2isox, 2H), 4.70 (br. s, 
OCHisox, 1H), 4.80 (br. s, NCHisox, 1H), 6.44–6.62 
(overlapped, ArH, 6H), 7.39 (br. s, ArH, 2H), 7.50 (br. s, 
ArH, 2H), 7.99–8.47 (overlapped, ArHpyrene, 9H) ppm. 
13
C 
NMR (100 MHz, CDCl3, 298K): δ = 10.30, 10.35, 23.24, 
23.33, 29.72, 30.96, 41.77, 44.02, 65.40, 69.30, 75.30, 76.90, 
77.24, 122.42, 122.57, 122.81, 123.44, 124.61, 124.81, 
124.95, 125.09, 125.38, 126.03, 127.47, 127.89, 128.38, 
128.45, 128.53, 128.81, 129.94, 130.23, 130.43, 130.56, 
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130.64, 130.73, 131.37, 134.20, 134.35, 135.47, 135.60, 
156.20, 161.25, 161.54, 166.46, 169.68 ppm. C63H65NO9 





Compound (±)-11a: 19 mg, 10% yield. ESI(+) MS: m/z = 
1280.4 [M + H]+. M.p. _180 °C (dec.). 
1
H NMR (400 MHz, 
CDCl3, 298 K): δ = 0.96 (t, J = 7.4 Hz, OCH2CH2CH3, 6H), 
1.01 (t, J = 7.3 Hz, OCH2CH2CH3, 6H), 1.83–1.99 
(overlapped, OCH2CH2CH3, 8H), 2.68 and 2.87 (br. AB, CH2 
isox, 4H), 2.80 (br. s, CH3N, 6H), 3.20 and 4.44 (AX, J = 13.2 
Hz, ArCH2Ar, 4H), 3.25 and 4.46 (AX, J = 13.2 Hz, 
ArCH2Ar, 4H), 3.75 (t, J = 6.8 Hz, OCH2CH2CH3, 4H), 4.02 
(t, J = 7.6 Hz, OCH2CH2CH3, 4H), 4.58 and 4.50 (AB, 
C(O)OCH2isox, 4H), 4.76 (br. s, OCHisox 2H + NCHisox 
2H), 6.22 (br. s, ArH, 4H), 6.37 (br. s, ArH, 2H), 7.65 (br. s, 
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ArH, 2H), 7.67 (br. s, ArH, 2H), 7.98–8.49 (overlapped, 
ArHpyrene, 18H) ppm. 
13
C NMR (100 MHz, CDCl3, 298K): 
δ = 10.15, 10.53, 23.28, 23.35, 30.95, 41.96, 44.14, 65.34, 
69.24, 75.10, 76.7, 76.9, 122.36, 122.63, 123.30, 124.46, 
124.82, 124.97, 125.06, 125.37, 126.03, 127.41, 127.48, 
127.86, 128.14, 130.26, 130.39, 130.65, 130.70, 131.39, 
133.57, 136.23, 155.76, 161.82, 166.47 ppm. C84H82N2O10 





Compound 12a: 15 mg, 8% yield. ESI(+) MS: m/z = 1280.4 
[M + H]+. M.p. _170 °C (dec.). 
1
H NMR (400 MHz, C6D6, 
298 K): δ = 0.84–0.91 (overlapped, OCH2CH2CH3, 12H), 
1.73–1.86 (overlapped, OCH2CH2CH3, 8H), 2.44 and 2.72 
(br. AB, CH2 isox, 4H), 2.73 (br. s, CH3N, 6H), 3.07 and 4.39 
(AX, J = 13.2 Hz, ArCH2Ar, 4H), 3.14 and 4.45 (AX, J = 
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13.6 Hz, ArCH2Ar, 4H), 3.65 (t, J = 7.2 Hz, OCH2CH2CH3, 
2H), 3.70 (t, J = 7.6 Hz, OCH2CH2CH3, 2H), 3.86 (t, J = 7.2 
Hz, OCH2CH2CH3, 4H), 4.54–4.69 (overlapped, 
C(O)OCH2isox, OCH, NCH, 8H), 6.25 (t, J = 7.4 Hz, ArH, 
2H), 6.41 (d, J = 7.4 Hz, ArH, 2H), 6.64 (d, J = 6.9 Hz, ArH, 
2H), 7.76–8.00 (overlapped, ArHpyrene, 22H) ppm. 
1
H NMR 
(400 MHz, CDCl3, 298 K): δ = 0.96 (t, J = 7.4 Hz, 
OCH2CH2CH3, 6H), 1.01–1.06 (overlapped, OCH2CH2CH3, 
6H), 1.85–1.99 (overlapped, OCH2CH2CH3, 8H), 2.66 and 
2.85 (br. AB, CH2isox, 4H), 2.79 (br. s, CH3N, 6H), 3.23 (d, J 
= 13.6 Hz, ArCH2Ar, 2H), 3.27 (d, J = 13.8 Hz, ArCH2Ar, 
2H), 3.72–3.78 (overlapped, OCH2CH2CH3, 4H), 4.04 (t, J = 
7.2 Hz, OCH2CH2CH3, 4H), 4.44–4.52 (overlapped, 
ArCH2Ar, 4H), 4.57 and 4.50 (AB, C(O)OCH2 isox, 4H), 
4.76 (br. s, OCH, 2H and NCH, 2H), 6.20–6.38 (overlapped, 
ArH, 6H), 7.70 (br. s, ArH, 4H), 7.98–4.49 (overlapped, 
ArHpyrene, 18H) ppm. 13C NMR (63 MHz, CDCl3, 298K): δ 
= 10.12, 10.57. 23.27, 23.37, 30.99, 41.77, 44.04, 65.28, 
69.22, 75.12, 76.82, 77.23, 122.40, 122.60, 123.29, 124.51, 
124.81, 124.96, 125.07, 125.37, 126.02, 127.47, 127.85, 
128.11, 128.83, 130.31, 130.41, 130.63, 130.70, 131.37, 
133.47, 136.33, 155.86, 155.90, 162.12, 166.70 ppm. 





Synthesis of Compounds 10b and 11b: Compound 1 (0.210 
g, 0.29 mmol) and (±)-2b (0.206 g, 0.65 mmol) were 
dissolved in dry pyridine (5 mL). The reaction mixture was 
stirred at room temperature for 24 h, and then the solvent was 
removed under reduced pressure. The pure products were 




Compound (±)-10b: 28 mg, 10% yield. ESI(+) MS: m/z = 
981.0 [M + H]+. M.p. _200 °C (dec.). 
1
H NMR (250 MHz, 
CDCl3, 298 K): δ = 0.94–1.05 (overlapped, OCH2CH2CH3, 
12H), 1.86–1.94 (overlapped, OCH2CH2CH3, 8H), 2.28–2.41 
(br. m, CH2isox, 1H), 2.73 (s, CH3N, 3H), 3.08–3.23 
(overlapped, ArCH2Ar, 4H and CH2 isox, 2H), 3.82–3.89 
(overlapped, OCH2CH2CH3, 8H), 4.23–4.53 (overlapped, 
ArCH2Ar, 4H and C(O)OCH2isox, 2H), 4.66–4.72 
(overlapped, OCH, 1H and NCH, 1H), 6.60–6.74 (overlapped, 
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ArH, 6H), 7.20 (s, ArH, 2H), 7.36 (s, ArH, 2H), 7.99–8.38 
(overlapped, ArHpyrene, 9H) ppm. 
13
C NMR (63 MHz, 
CDCl3, 298 K): δ = 10.24, 10.36, 10.39, 22.71, 23.18, 23.32, 
29.71, 30.32, 30.90, 41.06, 43.43, 65.95, 69.22, 76.72, 77.22, 
122.18, 122.43, 122.92, 123.64, 123.95, 124.17, 124.82, 
124.94, 125.08, 125.41, 125.45, 126.03, 127.40, 127.90, 
128.60, 128.71, 128.83, 129.85, 130.04, 130.18, 130.27, 
130.61, 130.65, 131.37, 132.53, 134.59, 134.96, 135.09, 
135.31, 156.45, 156.64, 160.82, 161.03, 166.69 ppm. 





Compound (±)-11b: 41 mg, 11% yield. ESI(+) MS: m/z = 
1280.4 [M + H]+. M.p. _170 °C (dec.). 
1
H NMR (400 MHz, 
CDCl3, 298 K): δ = 0.91 (t, J = 7.4 Hz, OCH2CH2CH3, 6H), 
1.07 (t, J = 7.3 Hz, OCH2CH2CH3, 6H), 1.84–1.97 
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(overlapped, OCH2CH2CH3, 8H), 2.31 and 3.20 (br. AX, CH2 
isox, 4H), 2.79 (br. s, CH3N, 6H), 3.16–3.22 (overlapped, 
ArCH2Ar, 4H), 3.69 (t, J = 6.3 Hz, OCH2CH2CH3, 4H), 4.04 
(t, J = 7.6 Hz, OCH2CH2CH3, 4H), 4.39–4.44 (overlapped, 
ArCH2Ar, 4H), 4.42 and 4.62 (AB, C(O)OCH2isox, 4H), 4.72 
(br. s, NCHisox, 2H), 4.79 (br. s, OCHisox, 2H), 6.13–6.21 
(overlapped, ArH, 6H), 7.73 (br. s, ArH, 4H), 7.99–8.42 
(overlapped, ArHpyrene, 18H) ppm. 
13
C NMR (150 MHz, 
CDCl3, 298K): δ = 9.98, 10.72, 23.17, 23.46, 30.86, 42.21, 
43.73, 66.46, 69.12, 74.84, 122.33, 122.40, 123.32, 124.20, 
124.85, 124.95, 125.08, 125.36, 125.49, 126.01, 127.32, 
127.49, 127.85, 128.68, 130.52, 130.60, 130.65, 131.38, 
132.88, 132.93, 133.17, 136.64, 155.32, 162.24, 166.78 ppm. 




Cell Viability Assays: FTC133, 8305C, and U87MG cell 
lines were seeded in 96-well plates. The cells were grown in 
an appropriate medium supplemented with 10% fetal bovine 
serum and incubated at 37 °C, 5% CO2 conditions, for 24 h 
before the cytotoxicity assessments. The cells were exposed to 
increased concentrations of the compounds. After 24 h of 
incubation, the cell survival was determined by MTT assay 
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according to the literature procedure.
106
 In brief, MTT 
solution [50 μL, 5 mg/mL in phosphate-buffered saline (PBS), 
Sigma] was added to each well and incubated for 2 h. The 
medium was subsequently removed from the wells, and the 
resulting formazan crystals were dissolved in DMSO (100 
μL). The culture plates were rocked gently for 30 min to 
dissolve the crystals before the optical density was measured 
at 570 nm with an enzymelinked immunosorbent assay 
(ELISA) microplate reader. In all ex periments, four replicate 
wells were measured for each drug concentration.  
 
 
Circular Dichroism: The CD spectra were recorded with 
samples in a standard quartz cell of 1 cm path length in the 
235–400 nm range. For each spectrum, five runs were 
averaged with a 5 min equilibration interval before each scan. 
All spectra were recorded at fixed poly(dA)–poly(dT) 
concentration (19.7 μm in base pair) in the absence or in the 
presence of different concentrations of 10b (4.3 mM solution 
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Preparation of Ligands: The 3D structures of the ligands 
were generated with the Winmostar (4.101) software,
107
 and 
all geometries were fully optimized with the same software 
with the semiempirical AM1
108
 Hamiltonian implemented in 
MOPAC2012 (14.04W).
109
 Compounds 10 were optimized as 
carboxylates (charge = –1). 
 
Molecular Dynamics Simulations: The molecular dynamics 
simulations of the DNA–ligand complexes were performed 
with the YASARA structure package (13.9.8).
52
 A periodic 
simulation cell with boundaries extending 10 Å from the 
surface of the complex was employed. The box was filled 
with water, and a density of 0.997 g/mL with explicit solvent 
was utilized. The pKa utility of YASARA was used to assign 
pKa values at pH = 7.2,
110
 the cell was neutralized with 22 
Na+ ions (23 for 10), and NaCl was added to reach 0.9% 
concentration by mass; under these conditions, ligands 10 
were deprotonated at the carboxylic acid function. Water 
molecules were deleted to readjust the solvent density to 
0.997 g/mL. The Amber03 force field was used with long-
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range electrostatic potentials calculated with the particle mesh 
Ewald (PME) method with a cutoff of 7.86 Å.
111
 The ligand 
force-field parameters were generated with the AutoSMILES 
utility,
112
 which employs semiempirical AM1 geometry 
optimization and assignment of charges, followed by 
assignment of the AM1BCC atom and bond types with 
refinement by using the restrained electrostatic potential 
(RESP) charges, and finally the assignments of general 
AMBER force field atom types. A short MD simulation was 
run for the solvent only. The entire system was then energy-
minimized through a steepest-descent minimization to remove 
conformational stress, followed by a simulated annealing 
minimization until convergence (< 0.01 kcal/mol Å). The MD 
simulation was then initiated; the NVT ensemble at 298 K was 
used, and the time steps for intramolecular and intermolecular 
forces were integrated every 1.25 and 2.5 fs, respectively. The 
MD simulation was stopped after 5 ns and, on the last frame, 
a second cycle of energy minimization, identical to the first, 
was applied. 
 
Docking Protocol: The DNA–ligand complexes, as obtained 
after coarse minimization or MD simulation and energy 
                                                 
111
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Cieplak, P.; Luo, R.; Lee, T.; Caldwell, J.; Wang, J. M.; Kollman, P. J. Comput. Chem. 
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minimization, were prepared with Vega ZZ
113
 (3.0.3.18) with 
Gasteiger charges assigned to the proteins and AM1BCC ones 
assigned to the ligands. The graphical user interface 
AutoDockTools (1.5.7 rc1)
114
 was used to establish the 
Autogrid points and to visualize the docked ligand–nucleic 
acid structures. Docking was performed with the AutoDock 
(4.2.5.1) software.
55
 To define all binding sites and to have 
structural inputs, a grid-based procedure was used.
115
 Here, 
the output was saved as a PDBQT file. The grid box was set 
and the output was saved as a gpf file. The ligand-centered 
maps were generated by the program AutoGrid (4.2.5.1) with 
a spacing of 0.375 Å and dimensions that encompass all 
atoms extending 10 Å from the surface of the ligand (for blind 
docking, DNA-centered maps were generated with a spacing 
of 0.375 Å and dimensions that encompass all atoms 
extending 10 Å from the surface of DNA). All of the 
parameters were inserted at their default settings. In the 
docking tab, the macromolecule and ligand were selected, and 
the GA parameters were set as ga_runs = 100, ga_pop_size = 
150, ga_num_evals = 2500000 for coarse docking and 
20000000 for fine docking, ga_num_generations = 27000, 
ga_elitism = 1, ga_mutation_rate = 0.02, ga_crossover_rate = 
0.8, ga_crossover_mode = two points, ga_cauchy_alpha = 0.0, 
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ga_cauchy_beta = 1.0, number of generations for picking 
worst individual = 10, output was selected as LGA, and the 




5.2 Biomolecular recognition abilities of 
calixarenes through the chemoproteomic 
approach 
 







synthesized according to literature procedures. SN38 (7-ethyl-
10-hydroxycamptothecin) and the known PDI inhibitor 16F16 
were purchased from Sigma-Aldrich. Molecular modeling 
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Derivative 19. A cold solution of acetyl chloride (1.76 mmol, 
0.125 mL) in dry THF (11 mL) was slowly added to a 
solution of tetraminocalix[4]arene derivative 18 (0.27 mmol, 
0.18 g) and dry Et3N (1.47 mmol, 0.20 mL) in dry THF (65 
mL) at 0 °C. The reaction mixture was allowed to warm at 
room temperature and stirred overnight. The solvent was then 
removed under reduced pressure. The crude product was 
dissolved in AcOEt, washed with a saturate solution of 
NaHCO3 (2 x 50 mL), with 1 M HCl (2 x 50 mL) and brine, 
dried over Na2SO4 and filtered. The solvent was removed by 
rotary evaporator. The product was purified by silica gel 
chromatography (AcOEt:MeOH, 7:3) (0.075 g; 33% yield); 
ESI(+)MS: m/z = 859.5 (M+Na+); 
1
H NMR (600 MHz, 
DMSO-d6, 298 K): δ 0.89-0.98 (overlapped, CH2CH2CH3, 
9H), 1.82-1.87 (overlapped, CH2CH2CH3, 6H ), 1.95 (s, 
C(O)CH3, 12H), 3.06 (d, ArCH2Ar, J = 12.8 Hz, 4H), 3.67-
3.81(overlapped, CH2CH2CH3, 6H), 4.29-4.71 (overlapped, 
OCH2C(O) + ArCH2Ar, 6H), 6.68 (s, ArH, 2H), 6.75 (s, ArH, 
2H), 7.04 (br s, ArH, 4H), 9.30 (s, NH, 1H), 9.35 (s, NH, 1H), 
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9.58 (br t, NH, 2H); 
13
C NMR (150 MHz, DMSO-d6, 298 K): 
δ 10.5, 11.1, 23.6, 23.7, 24.7, 24.4, 31.9, 32.4, 71.8, 78.2, 
78.3, 121.7, 121.9, 121.9, 133.6, 133.9, 134.3, 135.3, 135.5, 
136.6, 136.9, 153.9, 154.1, 154.8, 171.0, 171.2, 172.1. Anal. 






Derivative 22. A sample of 19 (0.09 mmol, 0.075 g) was 
dissolved in dry DMF (4.5 mL) and then HOBt (0.40 mmol, 
0.053 g) and DCC (0.40 mmol, 0.082 g) were added. The 
reaction mixture was stirred at room temperature for 1h. A 
solution of compound 21 (0.40 mmol, 0.100 g) in dry DMF 
(3.0 mL) was added to the reaction mixture, which was then 
stirred for 5 days. CH2Cl2 was added and the solution was 
washed sequentially with 1 M NaH2PO4 (3 x 15 mL), a 
saturate solution of NaHCO3 (2 x 15 mL), and water (2 x 15 
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mL). The organic phase was dried over Na2SO4 and filtered. 
The solvent was removed under reduced pressure and the 
product was purified by flash column chromatography on 
silica gel (AcOEt:MeOH, 85:15) (0.024 g, 22% yield); 
ESI(+)MS: m/z = 1071.2 (M+H+); 
1
H NMR (600 MHz, 
CD3OD, 298 K): δ 0.91 (t, CH2CH2CH3, J = 7.5 Hz, 3H), 1.02 
(t, CH2CH2CH3, J = 7.3 Hz, 6H), 1.44 (s, Boc, 9H), 1.85-2.11 
(overlapped, CH2CH2CH3 6H + C(O)CH3, 12H), 2.84 (t, 
CH2N, J = 6.6 Hz, 4H), 3.02 (t, CH2S, J = 6.6 Hz, 4H), 3.14-
3.25 (overlapped, ArCH2Ar, 4H), 3.76 (t, CH2CH2CH3, J = 
5.9 Hz, 2H), 3.88 (t, CH2CH2CH3, J = 7.3 Hz, 4H), 4.42-4.50 
(overlapped, ArCH2Ar, 4H), 4.79 (s, OCH2C(O), 2H), 6.60 (s, 
ArH, 4H), 7.21 (s, ArH, 2H), 7.24 (s, ArH, 2H); 
13
C NMR 
(150 MHz, CD3OD, 298 K): δ 10.5, 10.8, 23.8, 24.1, 28.8, 
30.8, 32.5, 32.79, 38.4, 39.4, 40.7, 75.1, 77.7, 78.9, 80.2, 
121.4, 121.8, 121.9, 122.4, 134.1, 134.4, 134.7, 135.3, 135.8, 
137.4, 152.8, 154.4, 155.1, 158.3, 171.0, 171.3, 173.2. Anal. 
Calcd for C56H74N6O11S2: C, 62.78; H, 6.96. Found: C, 62.87; 







pAc Derivative 13. A solution of 22 (0.022 mmol, 0.024 g) in 
CH2Cl2 (2 mL) was cooled at 0 °C. TFA (2 mL) was added 
and the reaction mixture was allowed to warm at room 
temperature and stirred for 5 h under nitrogen. CH2Cl2 was 
added and then the mixture was washed twice with a saturate 
solution of NaHCO3 and water. The aqueous phases were 
washed with AcOEt twice, the organic phases were dried over 
Na2SO4 and the solvent was removed under reduced pressure. 
The pure product 13 was purified by flash column 
chromatography on silica gel (AcOEt:MeOH, 48:52 and one 
drop of Et3N) (10.0 mg, 47% yield); ESI(+)MS: m/z = 971.4 
(M+H+), 993.48 (M+Na+); 
1
H NMR (300 MHz, CD3OD, 298 
K): δ 0.89 (t, CH2CH2CH3, J = 7.3 Hz, 3H), 1.01 (t, 
CH2CH2CH3, J = 7.3 Hz, 6H), 1.81-1.93 (overlapped, 
CH2CH2CH3 6H + C(O)CH3, 9H), 2.09 (s, C(O)CH3, 3H), 
2.86 (t, CH2N, J = 6.4 Hz, 4H), 3.02 (t, CH2S, J = 6.6 Hz, 
4H), 3.13-3.24 (overlapped, ArCH2Ar, 4H), 3.75(t, 
OCH2CH2CH3, J = 6.7 Hz, 2H), 3.86 (t, OCH2CH2CH3, J = 
7.2 Hz, 4H), 4.45 (overlapped, ArCH2Ar, 4H), 4.78 (s, 
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OCH2C(O), 2H), 6.57-6.59 (overlapped, ArH, 4H), 7.21 (s, 
ArH, 2H), 7.23 (s, ArH, 2H); 
13
C NMR (63 MHz, CD3OD, 
298 K): δ 8.90, 9.26, 22.2, 22.5, 22.6, 28.8, 28.9, 29.2, 30.8, 
31.2, 31.5, 36.7, 38.9, 39.1, 39.2, 73.6, 76.1, 77.4, 119.8, 
120.3, 120.4, 120.8, 132.6, 132.8, 133.7, 134.2, 135.9, 151.2, 
152.8, 153.6, 169.4, 169.7, 171.7. Anal. Calcd for 




Immobilization of pAC 13 on CDI-agarose beads: pAC 1a 
(3 μmol) (Scheme S1) was dissolved in ACN containing 40% 
NaHCO3 and 1.5% TEA and reacted with 300 μL of CDI-
Agarose beads for 16 h under rotary shacking at room 
temperature. Immobilization yield (30%) was assessed by 
injecting small aliquots of the reaction mixture in HPLC at t = 
0 and after 16 h of reaction (Figure 5.1). The 
chromatographic analysis was performed by using an Agilent 
1100 series chromatograph equipped with Phenomenex 
Jupiter C18, 5μm, 150x2.00 mm column at the flow rate of 
0.200 ml/min and evaluating the reduction of pAC 13 peak 
areas. After 16 h of reaction the supernatant was discarded 
and functionalized matrix was stored at 4 °C in acetone until 
usage. A control matrix was prepared by adding 1.5 μmol of 
TIOS, solubilized in the same reaction buffer, to 150 μl of 
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CDI-Agarose. Linker immobilization was established by 
analysing a small aliquot of beads with Kaiser test. Briefly, 
after extensive washings with ethanol, 20 μl of ninidrin (6% 
in ethanol), 20 μl of phenol (80% in ethanol), and 20 μl of 
KCN were added to the matrix. The development of a violet 
colour, indicating the presence of primary amines onto the 
beads surface, was detected after 5 min at 50 °C.  
 
 
Figure 5.1 Left panel shows the peak of free pAC 13 in 50 μL 
of reaction buffer at t = 0. The right panel 
shows the peak of free pAC 13 in 50 μL of reaction buffer 
after 16 h incubation. The reduction of the peak 








Synthesis of pAc derivative 24: A cold solution of acetyl 
chloride (5.22 mmol, 0.37 mL) in dry THF (32 mL) was  
added to a solution of tetraminocalix[4]arene derivative 23 
(0.79 mmol, 0.52 g) and dry Et3N (4.34 mmol, 0.60 mL) in 
dry THF (195 ml) at 0 °C. The reaction mixture was allowed 
to warm at room temperature and stirred overnight. The 
solvent was then removed under reduced pressure. The crude 
product was dissolved in AcOEt, washed with a saturate 
solution of NaHCO3 (2 × 50 mL), with 1 M HCl (2 ×50 mL) 
and brine, dried over Na2SO4 and filtered. The solvent was 
removed by rotary evaporator to give a yellow solid. The 
product 24 was purified by silica gel chromatography 
(CH2Cl2:MeOH, 95:5 v/v) (0.28 g; 43% yield). ESI(+)MS: 
m/z = 821.8 (M+H+), 844.5 (M+Na+), 860.3 (M+K+); 
1
H 
NMR (300 MHz, DMSO-d6, 298 K): δ 0.95 (t, CH2CH2CH3, 
J = 7.2 Hz, 12H), 1.83-1.91 (overlapped, CH2CH2CH3 8H + 
C(O)CH3, 12H), 3.04 (d, ArCH2Ar, J = 12.9 Hz, 4H), 3.75 (t, 
CH2CH2CH3, J = 7.2 Hz, 8H), 4.31 (d, ArCH2Ar, J = 12.9 Hz, 
4H), 6.86 (s, ArH, 8H), 9.45 (s, C(O)NH, 4H); 
13
C NMR (63 
MHz, DMSO-d6, 298 K): δ 10.5, 22.9, 24.0, 31.0, 76.7, 
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119.8, 133.4, 134.4, 152.2, 167.8. Anal. Calcd for 
C48H60N4O8: C, 70.22; H, 7.37. Found: C, 70.31; H, 7.29. 
 
 
Biomolecular fishing for partners: HeLa cells were grown 
in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with fetal bovine serum (10% (v/v)), penicillin 
(100 UmL-1), streptomycin (100 mgmL-1), glutamine (4 
mM), HEPES (10 mM), and sodium pyruvate (10 mM) at 37 
°C in a 5% CO2 atmosphere (all reagents were from Sigma–
Aldrich). The cells were collected by centrifugation (10000 
rpm, 3 min) and washed three times with phosphate saline 
buffer (PBS; sodium phosphate (50 mM), NaCl (150 mM), 
pH 7.5). Pellets were re-suspended in ice-cooled PBS 
containing Igepal (0.1%) and a protease inhibitor cocktail and 
lysed by dounce homogenation. Lysates were clarified by 
centrifugation at 10000g for 10 min at 4 °C and the protein 
concentration was determined using Bradford assay and 
adjusted to 1 mg/ml. pAC-13-beads (50 μL) and the same 
amount of the control-matrix were separately incubated with 1 
mg of HeLa total protein extract under continuous shaking (1 
h, 4 °C). Beads were then collected and washed three times 
with PBS (pH 7.4). Proteins strictly bound to solid matrices 
were isolated by breaking the disulphide bond contained into 
the TIOS linker with DTT 40 mM. The suspension was 
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maintained at 37 °C for 15 minutes to favor disulphide bridge 
cleavage. SDS-PAGE loading buffer (60 mM Tris/HCl pH 
6.8, 2% SDS, 0.001% bromophenol blue, 10% glycerol, 2% 
2-mercaptoethanol) was added to each sample and, after 5 
min at 95 °C, prior SDS-PAGE separation and Coomassie G-
250 (Bio-Rad, Hercules, CA) staining. In the attempt to 
evaluate the electrophoretic profile of the putative pAC-13 
partners, we run a 10% SDS PAGE. We coloured the SDS-
PAGE both by Comassie G-250 and by silver staining 
depending on the loading quantity. Since the run comparison 
between the calixbeads and the control (beads only) in the two 
SDS-PAGE profiles was not informative for our purpose, we 
decided to avoid the SDS-PAGE separation to reduce the 
protein loss due to the partition procedure, multiple in situ 
protein digestion, and peptide extraction. Then, in the 
following experiments, SDS PAGE was only used to purify 
proteins eluted prior digestion. More in details, proteins eluted 
from the beads were loaded onto SDS-PAGE but the 
separation was stopped after 10 minutes. Gels were stained 
with Coomassie G-250 (Bio-Rad, Hercules, CA), and the full 
short run, containing all proteins eluted from the beads, was 
cut out, washed with ultrapure water and CAN, and subjected 
to in situ protein digestion as described by Shevchenko.
117
 
                                                 
117




Briefly, each slice was reduced with 1,4-dithiothreitol (DTT, 
10 mM) and alkylated with iodoacetamide (50 mM), then 
washed and rehydrated in trypsin solution (12 ngmL
-1
) on ice 
for 1 h. After the addition of ammonium bicarbonate (30 μL, 
10 mM, pH 7.5), protein digestion was allowed to proceed 
overnight at 37 °C. Supernatants were collected and peptides 
were further extracted from gel slices using 100% acetonitrile. 
Finally, second supernatants were collected and combined 
with first ones. Peptide samples were dried and dissolved in 
formic acid (FA, 10%) before MS analysis. Peptide mixtures 
(5 μL) were injected into a nano-ACQUITY UPLC system 
(Waters) and separated on a 1.7 mm BEH C18 column 
(Waters) at a flow rate of 400 nLmin
-1
. Peptide elution was 
achieved with a linear gradient [solution A: H2O (95 %), 
CH3CN (5 %), FA (0.1%); solution B: CH3CN (95 %), H2O 
(5 %), FA (0.1 %); 15–50% B over 55 min]. Peptide samples 
re-suspended in formic acid (FA, 10%) and analysed with an 
ACQUITY UPLC system (Waters) coupled to a LTQOrbitrap 
XL (ThermoScientific). The ten most intense doubly and 
triply charged peptide ions were chosen for fragmentation. 
Mascot generic files (mgf) for database search were generated 
by the software MassMatrix MS data file conversion. 
Database searches were carried out on the Mascot server 
(http://www.matrixscience.com). The SwissProt database 
(release 2012_03, 21 March 2012, 535248 sequence entries, 
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189901164 amino acids abstracted from 208076 references) 
was employed. Searches were performed allowing two missed 
cleavages; carbamidomethyl (C) as fixed modification and 
oxidation (M) and phosphorylation (ST) as variable 
modifications; peptide tolerance 25 ppm; MS/MS tolerance 
0.8 Da. 
The entire fishing/control procedure was repeated 3 times 
(Experiments #1-3). In this way, three sets of potential 
protein partners for pAC 13 were obtained after excluding 
those of control experiments. The “pep(sig)” value represents 
the number of peptides found for the identified protein, while 
the protein Mascot score is the probability that the observed 
match is not a random event. A filter has been applied to 
select the proteins identified with high trustworthiness, 
reported in bold black, setting the value of pep(sig) >1 and 
protein Mascot score > 30. In gray are reported keratins (their 
presence is due to accidental operator contamination) and all 
the proteins identified with solely 1 pep(sig) and Mascot score 
≤ 30. The three sets of data were then intersected to exclude 
all not-common candidates. In this way, a single common 
protein was found, that was considered as the best potential 
specific partner of pAC 13, the protein disulfide isomerase 





Figure 5.2 Venn diagram showing the intersection of the 




Surface Plasmon Resonance: Protein disulphide isomerase 
(PDI, Enzo Life Sciences) and Peroxiredoxin 1 and Lamin b1 
(Origene), as negative controls, were immobilized onto CM5 
sensor chip using standard amine coupling procedures. HBSP, 
which consisted of 10 mM HEPES pH 7.4, 150 mM NaCl, 
0.005% v/v surfactant P20, was used as running buffer. The 
carboxymethyl dextran surface was activated as already 
described and proteins were diluted to a final concentration of 
30 ng/μl in 10 mM sodium acetate, pH 4.5 and injected 
separately onto the flow cells. After protein injections a DRU 
of ~10000 was recorded. The activated carboxymethyl 
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dextran surface was finally blocked with a 7-min injection of 
1.0 M ethanolamine-HCl, pH 8.5, at 5 μl/min. pAC 24 
solutions (0.1-10 μM), were prepared in running buffer 
containing 1% of DMSO and injected at least three times. 
Since the dissociation back to baseline was achieved within a 
reasonable time frame, no regeneration was required. The 
interaction experiments were carried out at a flow rate of 10 
μl/min. The dissociation time was set at 600 seconds. Rate 
constants for associations (ka) dissociations (kd) and the 
dissociation constants (KD) were obtained by globally fitting 
data from injections of all concentrations, using the BIA 
evaluation software, using the simple 1:1 Langmuir binding 
model (Figures 5.3-5.5). 
 
 
Figure 5.3 Sensograms obtained after injections of pAC 24 





Figure 5.4 Sensorgrams obtained after injections of pAC 24 
(three different concentrations, 0.1–10 μM) 





Figure 5.5 Sensorgrams obtained after injections of pAC 24 
(three different concentrations, 0.1–10 μM) 








Figure 5.6. Sensorgrams obtained after injections of pAC 24 
(three different concentrations, 0.1–10 μM) on 
the unfunctionalized SPR chip. 
 
 
Measurement of PDI activity: PDI activity was assayed by 
measuring the PDI catalysed reduction of insulin in the 
presence of DTT at 620 nm. Recombinant PDI protein (0.8 
μM) was incubated with pAC 24 (50 and 100 μM) at 37 °C 
for 30 min in sodium phosphate buffer (100 mM sodium 
phosphate). Later on, samples of the free and the recombinant 
PDI protein previously treated with pAC 24, were added to a 
mixture containing EDTA (2 mM), DTT (0.75 mM), and 
insulin (0.1 mM, Sigma). The reaction was allowed to 
proceed at room temperature and measured every 5 minutes at 
620 nm in a 96-well plate. Specific PDI activities, with and 
without the tested compound, were estimated by subtracting 
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Biological assays:  
Cell Lines 
The cell lines CAL-27 (oral adenosquamous carcinoma cell 
line) and PC-3 (human prostate cancer cell line) were grown 
in RPMI (Life Technologies, Paisley, UK) supplemented with 
10% heat-inactivated fetal bovine serum (FBS; Life 
Technologies), 2mM glutamine (Hyclone, Cramlington, UK), 
50 U/ml penicillin and 50 U/ml streptomycin (Hyclone), 
hereafter defined as CM. They were grown in adhesion 
culture, respectively, at a density of 3x105 cells per ml and 




PBMC was evaluated by MTS assay. Inhibition of cell 
metabolic activity was detected through formazan product 
formation, using a commercial colorimetric kit (MTS [3,4-(5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium salt]) (Cell Titer 96 Aqueous 
One Solution; Promega). This colorimetric standard assay 
measures the activity of the enzymes that reduce MTS to 
formazan. The assay was performed by seeding 5x103 CAL-
27 or PC-3 cells in 100 μl of CM per well in 96 wells plate in 
triplicate in absence or in the presence of 0.35, 0.75, 1.5, 3.0, 
6.0, and 12 μM of pAC 24, SN38 (7-ethyl-10-hydroxy-
camptothecin) and the known PDI inhibitor 16F16,
83
 as 
positive controls, for 24 hours. Twenty microliters of ‘Cell 
Titer 96 Aqueous One Solution’ reagent was added directly to 
culture wells at the end of the culture period and samples were 





The effect of pAC 24, SN38, and 16F16 on cytotoxicity of 
CAL-27 and PC-3 cell lines was assessed by evaluating dead 
and living cells, respectively, using the trypan blue dye 
exclusion test. After 24 hours of culture both CAL-27 and PC-
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3 cell lines were seeded in duplicate at 3x105 per well in the 
absence or in the presence of 0.35, 0.75, 1.5, 3.0, 6.0, and 12 
μM of pAC 24, SN38, and the known PDI inhibitor 16F16 as 
positive controls. After the incubation time, cells were stained 
with a colorant selective for dead cells, Trypan blue 0.1%, 
diluted in Phosphate buffered saline. The viable cells were 









24 CAL-27 20.5±0.8 31±4 
24 PC-3 24.5±0.9 283±10 














IC50  is the inhibitory concentration required to inhibit 50% of cell 
viability; 
b
CC50 is the metabolic activity cytotoxic inhibitory concentration 50%, 
evaluated in the CAL-27 and PC3 cell lines by MTS assay 
 
Table 5.1. Evaluation of the cytotoxicity of pAC 24 in 







Cumulative results from three or two determinations were 
used to calculate the initial compound concentration effective 
in inhibiting by 50% metabolic assay (CC50) or in inhibiting 
by 50% cell viability (IC50)±SD. The values were calculated 
according to the best-fit curve, y value versus log x, where y 




Docking studies: Docking calculations were performed with 
the AutoDock 4.2 program.
55
 The experimental structure of 
PDI in its reduced state
118
 was used for the calculations. 3D 
structures of the ligands were created and energy minimized 
with MacroModel-9.0/Maestro-4.14 program. For all the 
docked structures, all bonds at the upper rim were treated as 
active torsional bonds. Grid boxes of 80 Å, covering the four 
a, b, b', and a' domains, were used for the docking 
calculations (grid spacing = 0.375 Å). In particular, regarding 
the a and a' domains, the boxes were centered at the sulfur 
atoms of the catalytic residues C53 and C397 residues. In 
order to achieve a representative conformational space during 
the docking calculations, from three to ten calculations were 
                                                 
118
 Wang, C.; Li, W.; Ren, J.; Fang, J.; Ke, H.; Gong, W.; Feng, W.; Wang, C. C. 
Antioxid. Redox Signal 2013, 19, 36-45. 
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performed. The Lamarckian genetic algorithm was applied for 
sampling and default docking parameters were used with the 
following exceptions: ga-pop-size, 500; ga-num-evals, 
10000000; ga-num-generations 500000, and ga-run, 250. 
Docking studies were performed on pAC 24 derivative and 
pAC-13-bead model (Figure 5.8) to verify the accessibility of 
the matrix-bound calixarene (pAC-13-beads) into the enzyme 
active site without disrupting the PDI complex, as required by 
the pulldown experiments. Tetrapropxy-p-tert-
butylcalix[4]arene (TBC, Figure 5.8), devoid of the critical 
acetamido groups, was also studied as a comparative 
calixarene derivative and as a negative control case. The 
calculated inhibition constants (Ki) for these three derivatives 














Table 5.2. Calculated inhibition constants (Ki) of 





24 6.23 μM 
pAC-13-bead model 15.69 μM 




Synthesis of derivative 28: Compound 27 (50.0 mg, 0.07 
mmol) was dissolved in dry DMF (8.75 ml), then PyBOP 
(872.0 mg, 1.68 mmol), DIPEA (0.50 ml, 2.92 mmol) and N
α
-
Boc-Histidine (428.0 mg, 1.68 mmol) were added. The 
reaction mixture was stirred at room temperature for 72h then 
H2O (30ml) was added and the white precipitate was filtered. 
The product was purified by flash column chromatography 
(CH2Cl2:MeOH, 9:1).  












 = + 1.76 (c = 1, MeOH); 
1
H NMR (400 MHz, MeOD, 
298 K) δ 0.98 (t, OCH2CH2CH3, J = 7.4 Hz, 3H), 1.05 (t, 
OCH2CH2CH3, J = 7.4 Hz, 6H), 1.28 (t, OCH2CH3, J = 7.2 
Hz, 3H), 1.36-1.39 (overlapped, Boc, 36H), 1.93 (q, 
OCH2CH2CH3, J = 7.4 Hz, 4H), 1.96-2.03 (m, OCH2CH2CH3, 
2H), 2.91-3.02 (overlapped, CH2
histidine
, 6H), 3.11-3.18 
(overlapped, CH2
histidine
 + ArCH2Ar, 6H + 4H), 3.72-3.82 
(overlapped, OCH2CH2CH3, 4H), 3.90 (t, OCH2CH2CH3, J = 
7.8 Hz, 2H), 4.19 (q, OCH2CH3, J = 7.1 Hz, 2H), 4.32-4.36 
(m, CH
histidine





ArCH2Ar, 2H + 2H), 4.68 (d, ArCH2Ar, J = 12.9 Hz, 2H), 
4.84 (s, OCH2C(O)OCH2CH3, 2H), 6.55 (s, ArH, 2H), 6.76 (s, 
ArH, 2H), 6.94 (br s, CH
imidazole
, 4H), 7.00 (s, ArH, 2H), 7.03 
(br s, NCH
imidazole
, 4H), 7.14 (s, ArH, 2H), 7.96 (s, NH
imidazole
, 




C NMR (100 MHz, MeOD, 
298 K) δ 10.51, 11.00, 14.59, 24.36, 28.70, 30.47, 32.00, 
32.54, 56.16, 56.35, 61.61, 71.85, 78.24, 78.44, 80.93, 118.24, 
122.73, 132.86, 133.46, 135.36, 135.80, 136.70, 136.79, 





Synthesis of derivative 29: Compound 28 (31.2 mg, 0.019 
mmol) was suspended in dry THF (4.5 ml). A solution of 
LiOH
.
H2O (3.2 mg, 0.076 mmol) in H2O (0.9 ml) was added 
and the reaction mixture was stirred at room temperature for 6 
h. The solvent was removed under reduce pressure, then H2O 
(5 ml) and a few drops of 1M HCl solution were added until 
pH = 4-5 was reached. The product was thus concentrated and 
MeOH was added. The precipitate was removed by filtration 
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and the filtrate was concentrated affording compound 29. 







 = + 1.10 (c = 1, MeOH); 
1
H NMR (400 MHz, 
MeOD, 298 K) δ 0.92-0.96 (overlapped, OCH2CH2CH3, 6H), 
1.03 (t, OCH2CH2CH3, J = 6.6 Hz, 3H), 1.34-1.39 
(overlapped, Boc, 36H), 1.87-1.98 (overlapped, 
OCH2CH2CH3, 6 H), 3.01-3.25 (overlapped, CH2
histidine
 + 
ArCH2Ar, 8H + 4H), 3.78-3.82 (m, OCH2CH2CH3, 4H), 3.96-
4.00 (m, OCH2CH2CH3, 2H), 4.48-4.55 (overlapped, 
ArCH2Ar + CH
histidine
, 4H + 4H), 4.73 (s, OCH2COOH), 6.77 





, 2H + 4H + 4H), 7.44 (s, ArH, 




C NMR (100 
MHz, MeOD, 298 K) δ 9.97, 10.34, 10.86, 23.59, 24.01, 
24.23, 28.86, 29.40, 30.72, 31.59, 31.93, 32.33, 55.63, 55.79, 
78.71, 79.01, 80.37, 80.96, 118.65, 122.69, 131.53, 131.67, 
133.39, 135.15, 136.61, 137.05, 137.17, 149.22, 153.46, 





Synthesis of derivative 30: Compound 21 (409 mg, 1.62 
mmol) were dissolved in CH2Cl2 (16.2 ml), then DIPEA (0.55 
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ml, 3.24 mmol) and FmocCl (628 mg, 2.43 mmol) were 
added. The reaction mixture was stirred at room temperature 
for 1 h. Then water (10 ml) was added and the organic phase 
was collected, dried over Na2SO4 and concentrated. The crude 
product was dissolved in trifluoroacetic acid (16 ml) and the 
solution was stirred at room temperature for 45 min. 
Afterwards TFA was removed under reduced pressure, the 
crude was dissolved in CH2Cl2 and washed with NaHCO3 sat. 
sol. and brine. The organic phase was dried over Na2SO4 and 
the solvent was removed under reduced pressure. The pure 
product was isolated after silica gel chromatography 
(CH2Cl2:MeOH, 9:1) although the formation of a insoluble 
precipitate.  
(7% yield); ESI(+) MS: m/z = 354.5; 
1
H NMR (250 MHz, 
CDCl3, 298 K): δ 2.66 (t, CH2NH2, J = 6.2 Hz, 2H), 2.78 (t, 
CH2N, J = 5.9 Hz, 2H), 2.90-2.97 (overlapped, CH2S, 4H), 
3.08 (d, CH2
Fmoc
, J = 6.5 Hz, 2H), 4.06 (t, CH
Fmoc
, J = 6.5 
Hz), 7.25-7.41 (overlapped, ArH, 4H), 7.59 (t, ArH, J = 6.7 
Hz, 2H), 7.76 (t, ArH, J = 7.1 Hz, 2H); 
13
C NMR (63 MHz, 
CDCl3, 298 K): δ 38.94, 40.61, 42.52, 48.04, 48.28, 52.83, 







5.3 Multivalent iminosugar calix[8]arene 
conjugates 
 
Synthesis of derivatives 36-37: To a suspension of the 
desired calix[8]arene (1,0 g) in acetone (100 ml) Cs2CO3 
(1.25 eq. per OH) was added. The reaction mixture was stirred 
at reflux for 2 hours. Then the system was cooled to room 
temperature and propargyl bromide (2.5 eq. per OH) was 
added. The reaction mixture was then stirred at reflux for 20 
hours, then it was cooled to room temperature and the solvent 
was removed under reduced pressure. HCl 1N (150 ml) was 
added to the flask and the mixture was stirred for 15 mins. 
Then CH2Cl2 was added and the product was partitioned. The 
organic phases were collected, dried over Na2SO4 and the 
solvent was removed under reduced pressure. The crude 
product was dissolved in a small amount of CH2Cl2 and then 
MeOH was added. The precipitated was filtered, affording the 












H NMR (400 MHz, CDCl3, 
298K): δ 1.11 (s, tBu, 72H), 2.30 (br t, H
propargyl
, 8H), 4.10 (s, 
ArCH2Ar, 16H), 4.21 (d, OCH2C, 2.1 Hz, 16H), 6.95 (s, ArH, 
16H); 
13
C NMR (100 MHz, CDCl3, 298K): δ 31.19, 31.55, 
34.42, 60.87, 75.42, 79.70, 126.29, 133.39, 146.86, 153.06. 
 
 









H NMR (600 
MHz, CDCl3, 298K): δ 0.55 (s, tBu, 18H), 1.17 (s, tBu, 36H), 
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1.38 (s, tBu, 18H), 2.46 (br t, H
propargyl
, 4H), 2.56 (br t, 
H
propargyl
, 2H ), 3.56 (s, OCH2
xylene
, 4H), 4.10 (s, ArCH2Ar, 
8H), 4.21 (s, ArCH2Ar, 8H), 4.57 (s, OCH2
propargyl
, 8H), 4.74 
(s, OCH2
propargyl
, 4H), 5.95 (s, ArH, 4H), 6.70 (s, ArH, 4H), 
6.91 (s, ArH, 4H), 7.24 (br d, ArH, J = 2.2 Hz, 4H), 7.27 (s, 
ArH, 4H); 
13
C NMR (150 MHz, CDCl3, 298K): δ 30.97, 
31.09, 31.58, 31.83, 34.04, 34.51, 60.59, 61.45, 75.16, 75.63, 
80.04, 80.40, 124.58, 124.75, 126.31, 127.20, 128.29, 129.03, 
132.41, 133.10, 133.65, 134.94, 136.43, 146.25, 146.42, 




General procedure for the cycloaddition reactions: 
Compound 36/37 (10-15 mg) and DNJC6/DNJC9 (1.2 
eq/alkyne) were dissolved in DMF (0.8-1.0 ml) in an ACE 
pressure tube. Then a yellow solution of Cu2SO4
.
5H2O (0.1 
eq/alkyne) and sodium ascorbate (0.2 eq/alkyne) in water 
(0.2-0.25 ml) was added. The reaction mixture was heated 
under microwave irradiation for 20-30 min, in a common 
microwave oven (800 W). The mixture was concentrated, 
diluted in a 9:1:1 (v/v/v) solution of 
CH3CN/AcOEt/30w%NH4OH and filtrated with the same 
eluent (30 ml) on a small pad of SiO2. The filtrate was 
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Compound 38a: (AcOEt-AcOEt:MeOH 98:2, 51% yield); 
ESI(+) MS: m/z = 5250.74; [α]D
28.3
 = +3.59 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3, 298K): δ 0.89 (s, tBu, 72H), 1.25 
(br, H9+H10, 32H), 1.39 (br, H8, 16H), 1.77 (br, H11, 16H), 
2.00-2.04 (m, Ac, 96H), 2.30 (t, H1
a
, J = 10.6 Hz, 8H), 2.53 
(m, H7
a
, 8H), 2.61 (m, H5, 8H), 2.70 (m, H7
b
, 8H), 3.16 (dd, 
H1
b
, J = 11.6 Hz, J = 4.9 Hz, 8H), 4.06 (s, H15, 16H), 4.14 
(br, H6, 16H), 4.18 (overlapped, H12, 16H), 4.79 (s, H14, 
16H), 4.92 (m, H2, 8H), 5.03 (overlapped, H3+H4, 16H), 
6.80 (s, H16, 16H), 7.79 (s, H13, 8H); 
13
C NMR (75 MHz, 
CDCl3, 298K): δ 20.90, 20.96, 21.07, 24.79, 26.64, 26.91, 
30.17, 30.51, 31.41, 34.23, 50.19, 51.90, 53.13, 59.61, 61.65, 
66.63, 69.59, 69.68, 74.86, 123.90, 126.12, 133.29, 144.15, 






Compound 38b: (AcOEt:Petroleum Ether, 8:2, 52% yield); 
ESI(+) MS: m/z = 5587.11; [α]D
27
 = +5.21 (c = 1, CHCl3); 
1
H 
NMR (600 MHz, CDCl3, 298K): δ 0.90 (s, tBu, 72H), 1.24 
(overlapped, H9-H13, 80H), 1.39 (br, H8, 16H), 1.76 (br, 
H14, 16H), 2.00-2.06 (overlapped, Ac, 96H), 2.32 (t, H1
a
, J = 
10.9 Hz, 8H), 2.55 (m, H7
a
, 8H), 2.62 (br d, H5, J = 9.2 Hz, 
8H), 2.70 (m, H7
b
, 8H), 3.17 (dd, H1
b
, J = 11.4 Hz, J = 5.1 
Hz, 8H), 4.06 (s, H18, 16H), 4.14 (br, H6, 16H), 4.18 (br, 
H15, 16H), 4.79 (s, H17, 16H), 4.95 (m, H2, 8H), 5.0-5.07 
(overlapped, H3+H4, 16H), 6.80 (s, H19, 16H), 7.78 (s, H16, 
8H); 
13
C NMR (150 MHz, CDCl3, 298 K): 20.90, 20.97, 
21.07, 21.09, 24.84, 26.78, 27.48, 29.28, 29.74, 29.92, 30.57, 
31.43, 34.25, 50.31, 52.07, 53.18, 59.69, 61.60, 66.65, 69.66, 
69.74, 74.93, 123.86, 126.12, 133.30, 144.22, 146.57, 152.71, 









Compound 39a: (AcOEt/Petroleum Ether 9:1 - AcOEt, 51% 
yield); ESI(+) MS: m/z = 4364.31; [α]D
30.3
 = +3.99 (c = 1, 
CHCl3); 
1
H NMR (600 MHz, CDCl3, 298K): δ 0.40 (s, tBu16, 
18H), 0.95-1.54 (overlapped, H8-H10 + H12A, 44H), 1.17 (s, 
tBu20, 36H), 1.41 (s, tBu24, 18H), 1.86 (t, H11, J = 7.2 Hz, 










H5A + H5B + H7B
b
, 14H), 2.69-2.74 (m, H7A
b
, 4H), 3.10 
(dd, H1A
b
, J = 11.5 Hz, J = 5.22 Hz, 4H), 3.18 (dd, H1B
b
, J = 
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11.5 Hz, J = 5.2 Hz, 2H), 3.32 (s, H15, 4H), 3.44-3.48 
(overlapped, ArCH2Ar, 4H), 3.53 (t, ArCH2Ar, J = 14.4 Hz, 
4H), 3.86-3.97 (overlapped, H12A, 8H), 4.07-4.17 
(overlapped, H6A + H6B, 12H), 4.33 (t, H12B, J = 7.8 Hz, 
4H), 4.36-4.40 (overlapped, ArCH2Ar, 4H), 4.79 (d, 
ArCH2Ar, J = 13.2 Hz, 4H), 4.89-4.96 (overlapped, H3A + 
H3B, 6H), 4.97-5.08 (overlapped, H2A + H2B + H4A + H4B, 
12H), 5.82 (s, H17, 4H), 6.58 (s, ArH, 2H), 6.61 (s, ArH, 2H), 
6.95 (s, ArH, 2H), 6.98 (s, ArH, 2H), 7.22-7.28 (overlapped, 
ArH + H13B, 6H), 7.77 (s, H13A, 4H); 
13
C NMR (150 MHz, 
CDCl3, 298 K): δ 20.90, 20.97, 21.07, 24.41, 25.04, 26.58, 
26.70, 26.82, 29.92, 30.31, 30.39, 30.57, 31.14, 31.58, 31.88, 
33.92, 34.51, 34.54, 50.12, 50.45, 51.73, 51.92, 51.97, 53.06, 
53.19, 59.46, 59.69, 61.53, 61.60, 61.86, 66.18, 67.03, 69.60, 
69.69, 74.85, 75.00, 123.12, 123.26, 123.42, 124.04, 124.28, 
127.31, 128.71, 129.17, 132.72, 133.40, 134.63, 134.74, 
136.56, 144.05, 144.34, 146.49, 146.66, 152.42, 153.81, 






Compound 39b: (AcOEt/Petroleum Ether 72:28 – AcOEt, 
37% yield); ESI(+) MS: m/z = 4616.59; [α]D
31.6
 = +7.43 (c = 
1, CHCl3); 
1
H NMR (600 MHz, CDCl3, 298K): δ 0.41 (s, 
tBuH19, 18H), 1.05-1.30 (overlapped, H9-H13, 60H), 1.18 (s, 
tBuH23, 36H), 1.39 (s, tBuH27, 18H), 1.54 (br, H14A, 8H), 










, 6H), 2.61-2.64 (overlapped, 









, 6H), 3.34 (s, H18, 4H), 
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3.43 (d, ArCH2Ar, J = 14.4 Hz, 4H), 3.51 (d, ArCH2Ar, J = 
16.8 Hz, 4H), 3.89-3.99 (m, H15A, 8H), 4.10-4.17 
(overlapped, H6A + H6B, 12H), 4.33 (t, H15B, J = 7.3 Hz, 
4H), 4.39 (d, ArCH2Ar, J = 16.6 Hz, 4H), 4.78 (d, ArCH2Ar, 
J = 14.2 Hz, 4H), 4.92-4.97 (overlapped, H2A + H2B, 6H), 
5.00-5.08 (overlapped, H3A + H3B + H4A + H4B + H17A + 
H17B, 24H), 5.84 (s, ArH, 4H), 6.60 (s, ArH, 4H), 6.96 (s, 
ArH, 4H), 7.24 (s, ArH, 4H), 7,26 (overlapped, ArH + H16A, 
8H), 7.78 (s, H16B, 2H); 
13
C NMR (150 MHz, CDCl3, 298 
K): δ 20.90, 20.96, 21.06, 21.08, 21.27, 22.91, 24.65, 24.92, 
26.70, 26.72, 27.39, 27.51, 29.07, 29.18, 29.61, 29.67, 29.92, 
30.09, 30.42, 30.61, 30.76, 31.15, 31.59, 31.86, 32.14, 33.93, 
34.51, 50.31, 50.60, 51.99, 52.16, 53.16, 53.21, 59.66, 59.73, 
60.61, 61.53, 61.68, 66.24, 67.14, 69.66, 69.75, 74.93, 74.99, 
123.14,123.38, 124.05, 124.31, 127.34, 128.64, 129.21, 
131.92, 132.80, 133.39, 134.74, 136.66, 144.19, 144.40, 
145.88, 146.43, 146.51, 151.28, 152.43, 153.88, 169.96, 




General procedure for deacetylation reactions: The 
acetylated compound (10-15 mg) was dissolved in dry 
methanol (0.3-0.5 ml) and then NaOMe (0.45 eq/OAc) was 
added. The reaction mixture was stirred at room temperature 
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for 6 hours under nitrogen atmosphere. Methanol and water 
were added to dissolve the white precipitate formed. Dowex 
50WX8-200 ion-exchange resin was added until pH=6-7 was 
reached. Then the solution was filtered and concentrated to 





Compound 32a: 67% yield; ESI(+) MS: m/z = 3906.40; 
[α]D
33.3
 = +13.01 (c = 0.067, MeOH); 
1
H NMR (600 MHz, 
MeOD, 298 K): δ 0.96 (s, tBu, 72H), 1.26-1.29 (overlapped, 
H9+H10, 32H), 1.50 (br, H8, 16H), 1.73 (br, H11, 16H), 2.31 
(overlapped, H5, 8H), 2.34 (overlapped, H1
a
, 8H), 2.68 (m, 
H7
a
, 8H), 2.88 (m, H7
b
, 8H), 3.08 (dd, H1
b
, J = 11.7 Hz, J = 
5.04 Hz, 8H), 3.19 (t, H3, J = 9 Hz, 8H), 3.40 (t, H4, J = 9.2 
Hz, 8H), 3.53 (m, H2, 8H), 3.87 (br, H6, 16H), 4.09 (s, H15, 
16H), 4.19 (br, H12, 16H), 4.80 (br s, H14, 16H), 6.89 (s, 
H16, 16H), 7.96 (s, H13, 8H), 8.51 (s, OH); 
13
C NMR (150 
MHz, MeOD, 298 K): δ 25.07, 27.01, 27.48, 27.86, 28.21, 
30.43, 30.55, 30.86, 31.27, 32.07, 33.16, 35.23, 36.64, 51.26, 
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53.86, 57.17, 58.69, 67.55, 70.16, 71.42, 80.10, 125.94, 





Compound 32b: 82% yield; ESI(+) MS: m/z = 4242.77; 
[α]D
26.9
 = -4.15 (c = 0.24, MeOH); 
1
H NMR (600 MHz, 
MeOD, 313 K): δ 0.95 (s, tBu, 72H), 1.25 (overlapped, H9-
H13, 80H), 1.57 (br, H8, 16H), 1.76 (br, H14, 16H), 2.46-2.49 
(overlapped, H1
a
+H5, 16H), 2.80 (m, H7
a
, 8H), 3.00 (m, H7
b
, 
8H), 3.17 (dd, H1
b
, J = 11.28 Hz, J = 4.56 Hz, 8H), 3.23 (t, 
H3, J = 9.12 Hz, 8H), 3.45 (t, H4, J = 9.3 Hz, 8H), 3.57 (m, 
H2, 8H), 3.87 (dd, H6
a
, J = 11.88 Hz, J = 2.46 Hz, 8H), 3.94 
(dd, H6
b
, J = 12.06 Hz, J = 1.98 Hz, 8H), 4.07 (s, H18, 16H), 
4.21 (br, H15, 16H), 4.81 (s, H17, 16H), 6.88 (s, H19, 16H), 
7.96 (s, H16, 8H), 8.43 (br s, OH, 32H); 
13
C NMR (600 MHz, 
MeOD, 313 K): δ 25.04, 27.57, 28.25, 30.04, 30.29, 30.41, 
30.50, 30.56, 30.69, 30.80, 31.19, 31.30, 31.99, 33.02, 35.10, 
36.53, 49.85, 51.27, 53.99, 54.74, 56.60, 58.02, 67.39, 67.50, 





Compound 33a: 67% yield; ESI(+) MS: m/z = 3356.06; 
[α]D
29
 = -1.80 (c = 1, MeOH); 
1
H NMR (600 MHz, MeOD, 
298 K): δ 0.44 (s, tBuH16, 18H), 1.23 (s, tBuH20, 36H), 
1.24-1.49 (overlapped, H8-H10 + H11A, 44H), 1.48 (s, 




















3.20-3.24 (overlapped, H3A + H3B, 6H), 3.36 (s, H15, 4H), 
3.40-3.46 (overlapped, H4A + H4B, 6H), 3.52-3.58 
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(overlapped, H2A + H2B, 6H), 3.60-3.65 (overlapped, 
ArCH2Ar, 8H), 3.82-3.94 (overlapped, H6A + H6B + H12A, 
20H), 4.37-4.42 (overlapped, ArCH2Ar + H12B, 8H), 4.89-
4.96 (overlapped, ArCH2Ar + H14B, 8H), 5.15 (br s, H14A, 
8H), 5.86 (s, H17, 4H), 6.67 (s, ArH, 4H), 7.05 (d, H25, J = 
7.2 Hz, 4H), 7.36 (s, triazole, 4H), 7.39 (s, ArH, 4H), 7.42 (s, 
ArH, 4H), 8.28 (s, NH, 2H), 8.44 (br s, OH); 
13
C NMR (150 
MHz, MeOD, 298 K): δ 23.73, 24.51, 24.54, 24.75, 27.17, 
27.27, 27.60, 30.31,30.46, 30.61, 30.74, 31.05, 31.13, 31.29, 
31.87, 32.01, 32.22, 33.07, 34.86, 35.35, 35.36, 51.27, 51.32, 
53.66, 53.72, 56.37, 56.46, 56.70, 57.54, 58.10, 66.71, 67.32, 
67.37, 67.46, 69.40, 69.47, 69.72, 70.57, 70.96, 76.18, 79.48, 
79.53, 79.73, 125.05, 125.29, 126.13, 128.73, 129.83, 130.30, 
133.23, 133.25, 134.10, 134.87, 135.43, 137.75, 145.12, 














Compound 33b: 80% yield; ESI(+) MS: m/z = 3608.34; 
[α]D
29.5
 = -3.80 (c = 1, MeOH); 
1
H NMR (600 MHz, MeOD, 
298 K): δ 0.45 (s, tBuH19, 18H), 1.03-1.29 (overlapped, H9-
H13, 60H), 1.22 (s, tBuH23, 36H), 1.45 (s, tBuH27, 18H), 
1.48-1.56 (overlapped, H8A + H8B + H14A, 20H), 1.83 (m, 




 + H5A + 









, 6H), 3.09-3.14 (overlapped, 
H3A + H3B, 6H), 3.38 (s, H18, 4H), 3.40-3.45 (overlapped, 
H2A + H2B, 6H), 3.50-3.56 (overlapped, H4A + H4B + 
181 
 
ArCH2Ar, 14H), 3.85-3.97 (overlapped, H6A + H6B + H15A, 
20H), 4.36-4.42 (overlapped, H15B + ArCH2Ar, 8H), 4.87-
4.92 (overlapped, ArCH2Ar + H17A
a
, 8H), 5.11 (d, H17A
b
, J 
= 12 Hz, 4H), 5.16 (s, H17B, 4H), 5.89 (s, ArH, 4H), 6.67 (s, 
ArH, 4H), 7.02 (s, ArH, 4H), 7.35 (s, ArH, 4H), 7.36 (s, ArH, 
4H), 7.40 (s, triazole, 4H), 8.25 (s, H16B, 2H), 8.50 (br s, 
OH); 
13
C NMR (150 MHz, MeOD, 298 K): δ 23.68, 25.00, 
25.18, 27.43, 27.48, 28.28, 29.81, 29.97, 30.24, 30.36, 30.71, 
31.13, 31.27, 31.38, 31.73, 31.86, 32.04, 32.19, 34.87, 35.26, 
35.33, 51.42, 53.92, 54.76, 56.86, 57.00, 58.31, 58.57, 66.79, 
67.40, 67.46, 69.88, 70.04, 71.17, 71.34, 79.85, 79.98, 125.07, 
125.27, 126.02, 128.68, 129.71, 130.32, 133.30, 134.13, 
134.82, 135.60, 137.92, 145.25, 147.06, 147.82, 147.89, 














General Procedure for the CuAAC Reaction with trivalent 
dendron: Alkyne, azide, CuSO4·5H2O (0.1 equiv. per 
alkyne), and sodium ascorbate (0.2 equiv. per alkyne) in 
DMF/H2O (4:1, 2.5 to 5 mL) were successively added to a 5 
mL microwave reactor vial. The resulting suspension was 
heated under microwave irradiation at 80 °C for 30 min, then 
water (10 mL) was added, and the aqueous phase was 
extracted with EtOAc (3x12 mL). The organic phases were 
combined, dried with Na2SO4, and concentrated in vacuo. 
Traces of copper salts were removed by filtration through a 
short pad of silica. gel eluting with CH3CN/H2O/NH4OH 
(15:0.5:0.5), and the residue was then purified by flash 
chromatography (SiO2; CH2Cl2/MeOH, 99:1 to 95:5) to give 













Compound 43: 66% yield; MS (ESI, 
deconvoluted): m/z calcd for 





 = -3.30 (c = 1, 
MeOH); 
1
H NMR (CDCl3, 400 MHz): δ 
7.85 (br s, 8H, H-26), 7.57 (s, 24H, H-16), 
6.8 (br s, 16H, H-32), 5.10-4.99 (m, 48H, H-
3 and H-4), 4.98-4.91 (m, 24H, H-2), 4.81 
(br s, 5.3H, H-28), 4.51 (s, 48H, H-18),  
4.41 (br s, 10H, H-25), 4.33-4.27 (t, J = 7.4 
Hz, 48H, H-15), 4.14 (s, 48H, H-6), 4.03 (br 
s, 9.2H, H-24), 3.52-3.36 (m, 96H, H-19, H-
21, H-22 and H-23), 3.21-3.15 (dd, J = 
11.4, 5.0 Hz, 24H, H-1a), 2.76-2.66 (m, 
24H, H-7a), 2.65-2.60 (m, 24H, H-5), 2.59-
2.50 (m, 24H, H-7b), 2.35-2.28 (dd, J = 
10.9, 10.5 Hz, 24H, H-1b), 2.06 (s, 72H, 
OAc), 2.02-1.99 (several s, 216H, OAc*3), 
1.90-1.84 (m, 48H, H-14), 1.46-1.16 (m, 
288H, H8 to H-13), 0.97-0.72 (m, 72H, H-
35) ppm; 13C-NMR (CDCl3, 100 MHz): δ 
171.0, 170.4, 170.1, 169.9 (C=O, acetates), 145.3 (C-17 and 
C-27), 122.6 (C-16 and C-26), 74.9 (C-3), 70.4-69.8 (C-21, C-
22, and C-23), 69.7 (C-4), 69.6 (C-2), 69.4 (C-24), 65.2 (C-
18), 61.6 (C-5), 59.7 (C-6), 53.1 (C-1), 51.9 (C-7), 50.4 (C-
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15), 50.1 (C-25), 45.5 (C-20 and C-34), 31.3 (C-35), 30.5 (C-
14), 29.6, 29.2, 27.3, 26.7 (from C-9 to C-13), 24.9 (C-8), 







Compound 44: 48% yield; [α]D
20
 = + 4.4 (c = 1, MeOH); MS 
(ESI, deconvoluted) m/z calcd for C636H978N90O182 [M + 
14H]
14+
 913.9960; found 913.8864; 
1
H NMR (CDCl3, 400 
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MHz, 298K): δ 8.11-7.59 (m, 5.7H, H-26), 7.61-7.50 (m, 
18H, H-16), 7.38-7.16 (m, 8H, ArH), 6.96-6.58 (m, 4H, ArH), 
6.58 (s, 4H, ArH), 5.89-5.73 (m, 4H, A-9’), 5.16-4.99 (m, 
48H, H-3, H-4, H-A,B,C-7’), 4.99-4.91 (m, 18H, H-2), 4.89-
4.63 (m, 9H, H-A8, H-B8 and H-C8), 4.61-4.44 (m, 42H, H-
18 and H-25a), 4.36-4.22 (m, 42H, H-15 and H-25b), 4.14 (s, 
36H, H-6),  3.91-3.80 (m, 4H, H-24a), 3.78-3.63 (m, 8H, H-
24b), 3.54-3.31 (m, 72H, H-19, H-21, H-22 and H-23), 3.21-
3.15 (dd, J = 11.5 and 4.9 Hz, 18H, H-1a), 2.76-2.66 (m, 18H, 
H-7a), 265-2.60 (m, 18H, H-5), 2.59-2.49 (m, 18H, H-7b), 
2.35-2.28 (t, J = 10Hz, 18H, H-1b), 2.09-2.04 (s, 54H, CH3-
C=O), 2.03-2.00 (s, 108H, CH3-C=O), 2.01-1.98 (s, 54H, 
CH3-C=O), 1.93-1.79 (m, 36H, H-14), 1.49-1.10 (m, 288H, 
from H-8 to H-13, A-1’, B-1’ and C-1’) ppm; 
13
C NMR 
(CDCl3, 75 MHz, 298 K): δ 170.9, 170.4, 170.1, 169.8 (C=O, 
acetates), 162.6 (C-A3, C-B3, C-C3, C-A6, C-B7 and C-C7), 
145.42, 145.37 (C-15 and C-25), 144.2 (C-A4, C-B4 and C-
C4), 122.62, 122.53 (C-16 and C-26), 74.9 (C-3), 69.8 (C-4), 
69.6 (C-2), 69.5 (C-19, C-21, C-22, C-23 and C-24), 68.1, 
65.2 (C-18), 61.7 (C-5), 59.8 (C-6), 53.1 (C-1), 51.99, 51.95 
(C-7), 50.41, 50.38 (C-15 and C-25), 45.58, 45.55 (C-20), 
36.6, 34.44, 34.42 (C-A2, C-B2 and C-C2), 31.8, 31.6, 31.5, 
31.1 (C-A’, C-B1 and C-C1), 30.5 (C-14), 29.6, 29.2, 27.4, 
26.7, 25.8 (from C-9 to C-13), 25.10, 25.05 (C-8), 20.97, 
20.94, 20.85, 20.80 (CH3-C=O, acetates). 
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General procedure for the deacetylation reaction: 
Amberlite resin IRA 400 (6n g/mmol of substrate; n = number 
of acetate groups) was added to a solution of acetylated 
iminosugar in a mixture of MeOH/H2O (1:1), and the 
resulting solution was stirred for 4 h by using a rotary 
evaporator at atmospheric pressure. The resin was then 
removed by filtration and washed with methanol and water. 
The solvent was then removed from the filtrate under reduced 



















Compound 45: 89% yield; [α]D
20
 = - 2.6(c 
= 1, MeOH); MS (ESI, deconvoluted) m/z 
calcd for C616H1056N120O144 [M + 8H]
8+
 
1554.9796; found 1555.8798; 
1
H NMR 
(CDCl3, 400 MHz, 298K): δ 8.22-7.99 (br s, 
8H, H-26), 7.97-7.82 (s, 24H, H-16), 7.19-
6.59 (br s, 16H, H-32), 4.57-4.42 (m, 64H, 
H-18 + H-28, 48H+16H), 4.41-4.28 (m, 
48H, H-15), 3.84 (s, 48H, H-6), 3.54-3.32 
(m, H-2, H-4, and H-31, 48H + 16H), 3.20-
3.07 (m, 24H, H-3), 3.01-2.94 (dd, J = 11.9, 
5.5 Hz, 24H, H-1a), 2.83-2.71 (m, 24H, H-
7a), 2.62-2.50 (m, 24H, H-7b), 2.20-2.12 
(dd, J = 11.9, 11.5 Hz, 24H, H-1b), 2.12-
2.07 (m, 24H, H-5), 1.94-1.79 (m, 48H, H-
14), 1.55-1.38 (m, 48H, H-8), 1.39-1.17 (m, 
240H, from H-9 to H-13), 0.99-0.79 (m, 
72H, H-35)  ppm; 
13
C-NMR (CDCl3, 100 
MHz, 298K) δ 146.2 (C-17, C-27), 124.9 
(C-16, C-26), 80.6 (C-3), 72.1 (C-4), 70.8 
(C-2), 67.4 (C-5), 65.5 (C-18), 59.6 (C-6), 
57.8 (C-1), 53.8 (C-7), 51.4 (C-15), 32.1 (C-14), 31.4, 30.6, 





5.4 A new ligation strategy for the synthesis of 
glycoconjugates 
 
The galactosyl thioacetate 53 was synthesized according to 






Synthesis of compound 54: Galactosyl thioacetate 53 (92 
mg, 0.20 mmol) was dissolved in acetic acid (2.3 ml). Sodium 
acetate (272 mg, 2.0 mmol) and OXONE® (307 mg, 0.50 
mmol) were added and the reaction mixture was stirred at 
room temperature for 6 h. The product was filtrated, washed 
with AcOEt and purified by flash column chromatography 
(CH2Cl2:MeOH, 4:1). 94% yield; [α]D = +36.5 (c 1.0, 
MeOH). 
1
H NMR (400 MHz, MeOD, 298 K): δ 5.37 (t, 1H, 
J3,4 = 9.2 Hz, H-3), 5.03 (dd, 1H, J1,2 = 5.8 Hz, J2,3 = 9.5 
Hz, H-2), 4.96 (t, 1H, H-4), 4.26 (dd, 1H, J6a,6b = 12.2 Hz, 
J6a,5 = 5.4 Hz, H-6a), 4.20-4.15 (m, 1H, H-1), 4.11 (dd, 1H, 
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J6b,5 = 2.4 Hz, H-6b), 3.99 (ddd, 1H, J4,5 = 8.0 Hz, H-5), 2.90 
(t, 1H, J = 8.2 Hz, -CH2SO2-), 2.09, 2.06, 2.04 and 2.02 (4 s, 
12 H, 4 Ac), 1.82-1.68 (m, 2H, -CH2-). 
13
C NMR (75 MHz, 
MeOD, 298 K): δ 172.6, 171.7, 171.5, 171.4, 73.9, 72.0, 71.9, 
70.4, 70.0, 63.6, 51.9, 25.2, 22.0, 20.7, 20.6; HRMS (ESI/Q-
TOF) m/z for C17H25O12S (M
-






Synthesis of compound 55: Compound 54 (23.4 mg, 0.049 
mmol) was dissolved in dry DMF. SOCl2 (18 μl, 0.245 mmol) 
was added and the reaction mixture was stirred overnight 
under argon atmosphere. The product was concentrated and 
then dissolved in CH3CN (0.5 ml). Potassium fluoride (6 mg, 
0.10 mmol) and a catalytic amount of 18-crown-6 were added 
and the reaction mixture was stirred at room temperature 
overnight. CH2Cl2 was added and the mixture was filtrated. 
The filtrate was concentrated and the product was purified by 
flash column chromatography (AcOEt:Cyclohexane, 1:1). 
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52% yield; [α]D = +42.9 (c 1.0, CHCl3). 
1
H NMR (400 MHz, 
CDCl3, 298 K): δ 5.26 (t, 1H, J3,4 = 8.7 Hz, H-3), 5.06 (dd, 
1H, J2,3 = 9.0 Hz, J1,2 = 5.5 Hz, H-2), 4.92 (t, 1H, H-4), 4.24 
(dd, 1H, J6a,6b = 12.2 Hz, J6a,5 = 6.6 Hz, H-6a), 4.21-4.17 
(m, 1H, H-1), 4.09 (dd, 1H, J6b,5 = 2.5 Hz, H-6b), 3.86 (ddd, 
1H, J = 8.9 Hz, H-5), 3.47 (m, 2H, -CH2SO2-), 2.09, 2.06, 
2.05 and 2.04 (4 s, 12H, 4 Ac), 1.75-1.67 (m, 2H, -CH2-). 
13
C 
NMR (75 MHz, CDCl3, 298 K): δ 170.6, 169.9, 169.5, 169.5, 
71.5, 69.9, 69.8, 69.5, 68.5, 62.2, 50.1 (JC-F = 67.2 Hz), 23.8, 
20.6, 20.6, 20.6, 19.7; HRMS (ESI/Q-TOF) m/z calcd for 
C17H26FO11S (M+H)
+
 457.1180, found 457.1180. 
 
 
General procedure for the synthesis of sulfonamides: The 
reactions were performed in a sealed glass tube. Sulfonyl 
fluoride 55 (20 mg, 0.044 mmol) was dissolved in DMF. 
Then the desired amine (0.44 mmol) was added and the 
reaction mixture was stirred at 80 °C until full conversion of 
the sulfonyl fluoride (3-6 h). The solvent was removed under 
reduced pressure and the product was purified by flash 







Compound 56: (90% yield); [α]D = +33.1 (c 1.0, CHCl3). 
1
H 
NMR (400 MHz, CDCl3, 298 K): δ 7.39-7.31 (overlapped, 
5H, ArH), 5.26 (t, 1H, J3,4 = 9.1 Hz, H-3), 5.03 (dd, 1H, J2,3 
= 9.4 Hz, J1,2 = 5.7 Hz, H-2), 4.94 (t, 1H, H-4), 4.78 (t, 1H, J 
= 6.0 Hz, -NH), 4.30 (d, 2H, J = 6.0 Hz, -CH2N), 4.22 (dd, 
1H, J6a,6b = 12.1 Hz, J6a,5 = 5.7 Hz, H-6a), 4.13-4.09 (m, 
1H, H-1), 4.06 (dd, 1H, J6b,5 = 2.9 Hz, H-6b), 3.80 (ddd, 1H, 
J = 8.8 Hz, H-5), 3.00-2.88 (m, 2H, -CH2SO2-), 2.08, 2.04, 
2.03 and 2.02 (4 s, 12H, 4 Ac), 1.91-1.85 (m, 2H, -CH2-), 
1.77-1.70 (m, 1H, -CH2-), 1.55-1.52 (m, 1H, -CH2-). 13C 
NMR (75 MHz, CDCl3, 298 K): δ 170.8,170.0, 169.6, 169.5, 
136.9, 128.9, 128.1, 127.9, 72.0, 70.2, 70.1, 68.9, 68.8, 62.4, 
52.4, 47.2, 23.8, 20.7, 20.6, 20.6, 19.69; HRMS (ESI/Q-TOF) 
m/z calcd for C24H34NO11S (M+H)
+










Compound 57: (97% yield); [α]D = +37.2 (c = 0.9, CHCl3). 
1
H NMR (400 MHz, CDCl3, 298 K): δ 5.27 (t, 1H, J3,4 = 9.0 
Hz, H-3), 5.05 (dd, 1H, J2,3 = 9.4 Hz, J1,2 = 5.7 Hz, H-2), 
4.94 (t, 1H, H-4), 4.23 (dd, 1H, J6a,6b = 12.2 Hz, J6a,5 = 5.7 
Hz, H-6a), 4.19-4.13 (m, 1H, H-1), 4.07 (dd, 1H, J6b,5 = 3.0 
Hz, H-6b), 3.84 (ddd, 1H, J6b,5 = 2.7 Hz, J = 5.6 Hz, J = 8.8 
Hz, H-5), 3.30-3.21 (m, 1H, -NCH-), 3.11-2.98 (m, 2H, -
CH2SO2-), 2.09, 2.04, 2.02 and 2.01 (4 s, 12H, 4 Ac), 1.98-
1.94 (overlapped, 4H, -CH2-), 1.87-1.79 (m, 1H, -CH2-), 1.75-
1.55 (overlapped, 5H -CH2-), 1.35-1.15 (overlapped, 4H -
CH2-).  
13
C NMR (75 MHz, CDCl3, 298 K): δ 170.8, 170.0, 
169.6, 169.5, 72.0, 70.2, 70.1, 68.9, 68.8, 62.3, 53.2, 52.8, 
34.6, 25.1, 24.8, 23.9, 20.7, 20.7, 20.7, 20.6, 19.8; HRMS 









Compound 58: (45% yield); [α]D = +22.3 (c = 0.9, CHCl3). 
1
H NMR (400 MHz, CDCl3, 298 K): δ 5.29 (t, 1H, J3,4 = 9.1 
Hz, H-3), 5.07 (dd, 1H, J2,3 = 9.5 Hz, J1,2 = 5.8 Hz, H-2), 
4.97 (t, 1H, H-4), 4.24 (dd, 1H, J6a,6b = 12.2 Hz, J6a,5 = 5.6 
Hz, H-6a), 4.20-4.15 (m, 1H, H-1), 4.08 (dd, 1H, J6b,5 = 2.0 
Hz, H-6b), 3.84 (ddd, 1H, J = 9.0 Hz, H-5), 3.17 (t, 4H, J = 
7.8 Hz, -NCH2butyl-), 3.00-2.88 (m, 2H, -CH2SO2-), 2.11, 
2.06, 2.03 and 2.02 (4 s, 12H, 4 Ac), 2.03-2.92 (overlapped, 
2H, -CH2-), 1.87-1.78 (m, 1H, -CH2-), 1.71-1.62 (m, 1H, -
CH2-), 1.60-1.52 (m, 4H, -CH2butyl-), 1.28-1.20 (m, 4H, -
CH2butyl-), 0.94 (t, 6H, J = 7.3 Hz, -CH3butyl). 
13
C NMR (75 
MHz, CDCl3, 298 K): δ 170.7, 170.0, 169.6, 169.5, 72.0, 
70.2, 68.9, 69.7, 62.2, 50.9, 47.3, 31.0, 24.1, 20.7, 20.7, 20.6, 
19.9, 19.5; HRMS (ESI/Q-TOF): m/z calcd for C25H44NO11S 
(M+H)
+
 566.2635, found 566.2634.  
 
 
 
